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ABSTRACT 
Introduction: The primary study goal was to assess the feasibility of implementing a 
Randomized Clinical Trial (RCT) of Mindfulness-Based Relapse Prevention (MBRP) in 
a substance use and methadone clinic using a neuropsychological framework.  
Methods: Participation interest, retention rates, and feasibility of study design were 
examined. 13 participants were randomized to waitlist (n = 6) or MBRP (n =7). 
Associations between baseline variables and retention were examined. Executive function 
(EF) performance and topological properties of fNIRS resting-state networks were 
assessed.  
Results: Power was limited, but quantity of outside treatment was associated with 
retention. EF was variable, but within the average range. Network analyses revealed 
small world parameters in resting-state networks using fNIRS. Exploratory correlation 
analyses between EF and graph metrics were performed.  
Conclusions: The feasibility of using neuropsychological measures of EF and fNIRS in 
the context of a RCT in an outpatient substance use clinic was demonstrated.   
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 1 
INTRODUCTION 
  
 Each day roughly 130 people will die following an opioid overdose in the United 
States; and these rates continue to rise (NIDA, 2019b).  Between 2016 and 2017 overdose 
deaths from fentanyl, for instance, increased by 45 percent (Scholl, Seth, Kariisa, Wilson, 
& Baldwin, 2018).  The rate of overdose deaths associated with opioids in New Mexico 
remains well above the national average (NIDA, 2019a). Opioid Use Disorder (OUD) has 
been associated with increased psychiatric and comorbid substance use problems.  In 
particular, previous use of other substances of abuse appears to be the norm rather than 
the exception. For instance, while a prior anxiety disorder diagnosis increased the odds of 
later developing an OUD by 50%, a prior substance use disorder (SUD) diagnosis 
increased the odds of developing an OUD by 300% (Blanco & Volkow, 2019).  While 
medical interventions may be the first line of treatment for OUD, given the chronic and 
relapsing nature of OUD, behavioral interventions are needed particularly after patients 
are stabilized.  Despite a significant need for more effective interventions, there remains a 
significant gap in the literature on the best psychosocial interventions (Dugosh et al., 
2016).   
 There is clear need for additional treatment approaches for OUD.  Advances in 
neuroimaging and clinical neuroscience have fueled interested in identifying new 
treatment targets for OUD via a neuropsychological approach (Ieong & Yuan, 2017; 
Stewart, May, Aupperle, & Bodurka, 2019).  A neuropsychological framework to mental 
health can help identify new targets for treatment and assess changes in those markers 
over time through the use of neuropsychological assessments, neuroimaging methods and 
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self-reported symptoms.  Following a brief overview of current treatments for OUD, a 
neuropsychological framework will be employed for the remainder of the paper.   
Opioid Use Disorder: Treatment As Usual 
 Broadly, OUD treatments can be divided into three different approaches based on 
the treatment goal: crisis intervention (in context of overdose), medication-
assisted/maintenance treatment, and abstinence-based intervention(Hser, Evans, Grella, 
Ling, & Anglin, 2015; Van den Brink & Haasen, 2006).  While crisis intervention is 
beyond the scope of this paper, it is worth noting that this stage of treatment is when most 
individuals with an OUD seek treatment, with one in four individuals seeking additional 
treatment in the following month.  Abstinence-oriented interventions occur in two phases: 
detoxification and relapse prevention.  In general, treatment outcomes have been 
disappointing and appear effective for a relatively small subset of individuals with OUD 
with high social support, stable environments and high levels of motivation (Van den 
Brink & Haasen, 2006).  Medication-assisted treatments (MAT)have greater success rates 
and emphasize a harm reduction approach to treatment. MAT involves one of three FDA-
approved medications: methadone, buprenorphrine, and naltrexone(Connery, 2015).  All 
three medications target the mu-receptor: methadone is a full agonist, buprenorphrine is a 
partial agonist, and naltrexone is an antagonist.  In a recent review of RCTs of 
methadone, buprenorphine and naltrexone, the efficacy of these medications for 
prevention of opioid relapse and continuation in treatment has been 
demonstrated(Connery, 2015).  Of the three, Methadone remains the gold standard for 
OUD treatment.   
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 Methadone Maintenance Therapy (MMT), a type of opiate replacement therapy 
(ORT), has been associated with decreased likelihood of overdose, reduced contraction of 
HIV/Hepatitis C among intravenous drug users, and has been shown to enable individuals 
to have more functional lives through reduction of criminal risks and increased ability to 
gain employment (WHO, 2009).  Despite this success, mortality rates in long-term cohort 
studies of individuals receiving methadone, nonetheless, were 6 to 20 times greater than 
that of the general population, and 25-50% of the cohorts were deceased 20 years after 
baseline (Hser et al., 2015). The authors suggest mortality rates were impacted by AIDS 
among areas with high HIV prevalence, and impacted by suicide and trauma in countries 
with lower rates of HIV/AIDS (Hser et al., 2015). 
 A number of behavioral interventions have been used in conjunction with MMT 
and include: contingency management, 12-step recovery, cognitive behavioral therapy, 
motivational interviewing, risk reduction counseling, Acceptance and Commitment 
Therapy (ACT), general therapy, and supportive counseling (Dugosh et al., 2016).   
However, most research has focused on contingency management and cognitive 
behavioral therapy in conjunction with methadone maintenance (Dugosh et al., 2016).  
While research has supported the incremental value of using behavioral interventions in 
conjunction with ORT, success varies based on treatment outcomes and comparison 
groups.  
 A significant majority of individuals reporting symptoms of OUD report no 
treatment (L. T. Wu, Zhu, & Swartz, 2016). Given the risks associated with OUD this is 
concerning. Further, even among individuals that eventually seek treatment, most 
individuals reported use of opioids 6 to 10 years before initiating treatment (Hser et al., 
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2015). In addition to the limited access to treatment and delays in treatment seeking, 
among patients that initiate treatment, there are high drop-out rates that are concerning.  
Research has shown that patients that remain in MMT for longer periods of time have 
better treatment outcomes. The first year of treatment appears to be especially critical 
(Hser et al., 2015). However, there is a vast literature suggesting the majority of patients 
drop out of treatment in the first year. Furthermore, in outpatient settings, drop-out rates 
are even higher than in randomized controlled trials (Roberts, 2018).  Efforts to identify 
and ameliorate barriers to treatment are of great interest. In particular, individuals using 
prescription opioids and individuals who are adolescent or from ethnic minority 
backgrounds are less likely to receive care (F. Wu, Fu, & Hser, 2015). There is a 
significant need to target prevention and treatment efforts towards these populations.   
Concerns with Treatment As Usual 
 While ORTs have undoubtedly reduced rates of overdose deaths and contraction 
of HIV/Aids and Hepatitis C, the high rates of drop and low treatment engagement 
suggest more can be done to improve treatment. The MMT phase of treatment may last 
for years or for the patients’ life. There remains among providers, a debate as to whether 
efforts should be made to facilitate discontinuation of methadone treatment or whether it 
should remain a lifelong option (Schuckit, 2016). On the one hand, some individuals 
seeking ORT may perceive it as an alternative to criminalization (Frank, 2018), 
alternatively, for individuals seeking to eventually discontinue methadone, this may not 
be perceived as a good fit either. 
 ORT is generally provided at outpatient substance use clinics, methadone clinics, 
or inpatient substance use settings.  Access to specialty clinics may be an additional 
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barrier, particularly among individuals with limited transportation or those that live in 
rural communities (Amiri et al., 2018; Sigmon, 2014).  Alternative models of care 
including, primary-care-based models have been explored, with the hope of increasing 
access to care (Korthuis et al., 2017).  Even among individuals receiving treatment at 
outpatient substance use clinics, there has been concern that individuals are not always 
prescribed the most effective medication or are prescribed doses that were below the 
effective dose.  In 2011, for instance, in a nationwide sample of patients on MMT, 41 
percent of the sample received doses that were too low to be optimally effective 
(D'Aunno, Park, & Pollack, 2019).  
 Historically, under-dosing of methadone had been a clinical concern. Notably 
while this pattern has improved within the general population, among ethnic minorities 
this remains a significant clinical concern (D'Aunno et al., 2019).  Further, treatments 
may not adequately serve all individuals.  Research assessing gaps in access to care has 
found that individuals from different cultural backgrounds may find the MMT approach 
inadequate.   For instance, a recent qualitative study interviewed 53 Latino and African 
American individuals that were using intravenous drugs but had declined to continue 
receiving treatment at a methadone clinic (Zaller, Bazazi, Velazquez, & Rich, 2009). The 
authors identified specific beliefs related to discontinuing treatment, including belief that 
methadone was harmful to one’s health, perception that methadone should be 
discontinued, and belief that one cannot be abstinent from substances of abuse if on 
MMT.  Additionally, financial burden and the time requirements for treatment were 
barriers noted.    
Opioid Use Disorder Complexity 
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 ORT may not sufficiently address the range of complexity observed within this 
population. While substance use disorders are diagnosed for the individual substance of 
abuse, instances of comorbid substance use disorders remain a clinical issue.  A recent 
publication using the National Epidemiological Survey on Alcohol and Related 
Conditions (NESARC) data examined prevalence of multiple substance use disorder 
diagnoses at two time points (McCabe & West, 2017). The authors found individuals 
diagnosed with multiple SUDS at time point one were more likely to exhibit a SUD at 
time point two, relative to individuals diagnosed with one SUDs at time point one. 
Further, the authors found individuals with multiple SUDs were less likely to receive any 
SUD treatment relative to individuals with a single SUD (McCabe & West, 2017).  
Among OUD samples, research from the 2015-2017 National Survey on Drug Use and 
Health data found significant rates of co-occurring drug and alcohol use among adults 
diagnosed with an OUD (Jones & McCance-Katz, 2019). More specifically, the rate for 
co-occurring SUDs ranged from 26.4% for alcohol to 10.6% for methamphetamine 
(Jones & McCance-Katz, 2019). Among individuals with OUD, 57.3% met criteria for 
polydrug use disorder, with alcohol as the most frequently reported substance used in 
addition to opioids (Hassan & Le Foll, 2019).  Further, polydrug use among individuals 
with an OUD may be associated with greater psychopathology, including PTSD (Hassan 
& Le Foll, 2019). While polysubstance use disorder was not included in the latest 
iteration of the Diagnostic and Statistical Manual of Mental Disorders (DSM), use of 
multiple substances, particularly among OUD clients remains an important clinical 
concern.   
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 Adults with an OUD exhibit elevated rates of psychopathology. More specifically, 
64.3% of adults with an OUD experienced mental illness in the past year and 26.9% 
experienced serious mental illness within the past year (Jones & McCance-Katz, 2019). 
Among those individuals with OUD that experienced mental illness in the past year, 
24.5% reported receiving treatment for both substance and mental health concerns, while 
29.6% of individuals with OUD and serious mental illness reported receiving treatment 
for both conditions. Among a sample of treatment seeking individuals with a SUD, 32% 
reported a past suicide attempt and of those, 59% reported a serious attempt (Icick et al., 
2017). Clearly, more comprehensive interventions that address the complexity of OUD 
are needed.  
 While ORTs have the potential to greatly improve the lives of individuals with an 
OUD, they are unfortunately underutilized. In part, perhaps, because ORTs do not 
address the prevalent comorbid substance use and mental health concerns in this 
population.  Interventions are needed that can simultaneously address substance abuse 
and comorbid mental health issues.  Mindfulness-Based Interventions (MBIs) show great 
promise in this respect.   
Mindfulness-Based Interventions (MBIs) 
 MBIs are being increasingly used in the treatment of a wide range of psychiatric 
conditions (Alfonso, Caracuel, Delgado-Pastor, & Verdejo-Garcia, 2011; Hofmann, 
Sawyer, Witt, & Oh, 2010; Witkiewitz & Bowen, 2010). The vast majority of MBIs are 
based on Mindfulness-Based Stress Reduction (MBSR) during which individuals learn 
ways to practice techniques to increase mindfulness, defined broadly as “…paying 
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attention in a particular way: on purpose, in the present moment, and nonjudgmentally” 
(Bowen, Chawla, & Marlatt, 2011).  
 MBIs have shown efficacy for individuals with SUDs and have been shown to 
reduce both substance use behavior and self-reported craving across a variety of 
substance-using samples (Bowen et al., 2014; Chiesa & Serretti, 2014; Witkiewitz & 
Bowen, 2010; Witkiewitz et al., 2014).  One prominent approach, Mindfulness-Based 
Relapse Prevention (MBRP) has been shown to reduce craving and prevent relapse in 
individuals with an SUD via improved mood (Witkiewitz & Bowen, 2010) and 
acceptance of thoughts (Witkiewitz et al., 2014).  
 Implementing MBRP within an outpatient methadone clinic is relatively novel. 
Recently, Bowen and colleagues (2017) conducted a pilot study of clients receiving 
treatment at a MMT clinic (Bowen, Somohano, Rutkie, Manuel, & Rehder, 2017). In that 
study, 15 individuals completed the baseline visit, and seven completed the follow up 
visit. Participants in the study were recruited from a community-based methadone clinic. 
Average age of the sample was 43.8 years (ages 27 to 65 years old), the majority of the 
sample were white (93%) and employed full-time (87%). Regarding clinical variables, 
over half had a history of inpatient substance use treatment and the majority of the 
sample was concurrently participating in a 12-step program.  Preliminary results based on 
direction and magnitude of mean change suggested improvements in outcome associated 
with MBRP. The largest effect size was for change in craving (g = 0.98, p = .032). 
Medium effect size for change in mood and a smaller effect size for change in trauma-
related symptoms was also found (g = 0.63, p = .03; g = 0.09, p = .025).  A second study 
examined the impact of MBRP on relapse and self-report ratings of impulsivity among 
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patients receiving MMT (Yaghubi, Zargar, & Akbari, 2017).  Seventy patients referred to 
MMT centers in Iran were randomized to receive either, treatment as usual (TAU) or an 
8-week MBRP group.  Lower rates of relapse were observed in the MBRP group 
immediately following the intervention (p = 0.012) and at a two month follow up visit (p 
= .010).    Relative to the TAU group, the MBRP group scored significantly lower on a 
self-report measure of impulsivity, the Barrett Impulsivity Scale (BIS-11) (p < .001), 
immediately following the intervention. The drop in self-reported impulsivity remained 
two months following the completion of the intervention.  While potential mechanisms of 
action associated with MBRP are still being explored, executive function (EF), which 
includes impulsivity, has shown great promise as a possible treatment target for SUDs 
and as a possible mechanism by which MBIs work. 
Definitions and Measures of Executive Function 
 Broadly, executive function (EF) refers to a set of interrelated cognitive processes 
that enables one to carry out goal-directed behavior and inhibit prepotent (automatic) 
responses (Kramer et al., 2014; Lezak, Howieson, & Loring, 2004; Miyake et al., 2000).  
Various models of EF have been proposed.  One distinction that has particular application 
to SUD is that of “cool” EFs and “hot” EFs.  Namely, while “cool” EF refers to abilities 
in a context-free environment, “hot” EF refers to those abilities in affective contexts 
(involving emotion, motivation, reward).  Typically, the EF tasks used in lab and clinic 
settings are “decontextualized”, meaning they do not have an “affective or motivational 
component” (Prencipe et al., 2011).  
 Miyake and Friedman’s model of EF (Miyake et al., 2000), a well validated, 
developmentally relevant model of EF captures the cool EFs, including: updating, 
 10 
shifting, and inhibitory control. While this model was originally tested within typically 
developing adults, a longitudinal study examining individuals performance on measures 
of EF during late adolescence and young adulthood, found the unity/diversity model of 
EF was supported (Friedman et al., 2016).   
 Cool EF can be measured with neuropsychological tasks that measure: updating 
and monitoring working memory; shifting between tasks or mental sets; and inhibiting 
dominant or prepotent responses (Miyake et al., 2000). Given the multifactorial nature of 
EF, a single score on a test does not sufficiently capture the construct of interest, which, 
in part motivated the creation of The Delis-Kaplan Executive Function System (D-
KEFS), a widely used battery of EF tests.  
 In more recent years, efforts to develop computerized tasks of EF have been 
made. The National Institute of Health (NIH) Toolbox for the Assessment of 
Neurological and Behavioral Function (NIH-TB) Cognitive Battery measures EF across 
the lifespan at multiple time points. The Toolbox contains multiple measures of EF that 
map well onto Miyake and Friedman’s model of EF, including: Dot Counting and N-back 
(updating), Set Shifting (shifting) and Flanker (Kramer et al., 2014; Macleod, 1992).  
 Hot EFs continue to develop during late adolescence into young adulthood and 
involve: affect intensity and reactivity (having to do with the initial affective response) 
and affective modulation, cognitive modulation and behavioral control (domains more 
related to top-down control of emotion) (Wilcox, Pommy, & Adinoff, 2016). Hot EF can 
be measured with self-report and tasks that measure: negative affect, reactivity, and 
coping with emotions. Examples of tasks and self-report measures of hot EF include: 
Difficulties in Emotion Regulation Scale (DERS) and White Bear Suppression Index 
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have been tied to hot EF in substance use disorders (H. C. Fox, Axelrod, Paliwal, Sleeper, 
& Sinha, 2007; H. C. Fox, Hong, & Sinha, 2008; Garland, Carter, Ropes, & Howard, 
2012; Toll, Sobell, Wagner, & Sobell, 2001).  
 The neuroanatomical correlates of EFs have been examined using both structural 
and functional neuroimaging studies (Friedman & Miyake, 2016). While EF typically 
involves multiple brain regions, they are often associated with the prefrontal cortex (PFC) 
(Otero & Barker, 2014; Stuss & Alexander, 2007). Based on lesion studies, cool EFs are 
frequently localized to dorsolateral PFC and the anterior cingulate cortex, hot EFs are 
typically localized to ventromedial PFC (Robinson, Calamia, Glascher, Bruss, & Tranel, 
2014).  There is some evidence to suggest specific properties of neural networks may be 
correlated with specific EFs, as well (Reineberg, Gustavson, Benca, Banich, & Friedman, 
2018). 
Neurodevelopmental Correlates of Executive Function   
 Many of the neurodevelopmental changes that occur in the PFC during 
adolescence and young adulthood have been linked to the protracted development of EF 
(Asato, Terwilliger, Woo, & Luna, 2010; Barnea-Goraly et al., 2005; Squeglia, Jacobus, 
Sorg, Jernigan, & Tapert, 2013). Substance use during adolescence and young adulthood 
has the potential to disrupt these developmental processes in clinically significant ways.   
 In particular, EF development during adolescence has been associated with 
increased within-PFC connectivity, increased PFC activation at rest and during EF tasks, 
as well as changes in the topological features of connectivity (Fair et al., 2007). 
Developmental changes in within-PFC connectivity can be observed in both structural 
connectivity and functional connectivity. For instance, during adolescence increasing age 
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is positively correlated with increasing structural integrity of white matter within the 
prefrontal cortex (Barnea-Goraly et al., 2005). Further, white matter connectivity in tracts 
connecting PFC to PFC (e.g., genu of the corpus callosum) continue to develop during 
adolescence (Asato et al., 2010).  Functional connectivity analyses provide further 
support.  For instance, decreased short-range connectivity and increased long-range 
connectivity  and reduced white matter integrity of the genu of corpus callosum has been 
associated with higher scores on a self-report measure of EF behaviors (Clark, Chung, 
Thatcher, Pajtek, & Long, 2012).   
 SUDs have been associated with aberrant development of these neurobiological 
pathways. Further, given the increase in substance use during adolescence, the use of 
drugs and alcohol also directly impact the development of the neural circuits underlying 
EF.  While additional deficits have been associated with SUD, broadly, EF in particular is 
tied to neurodevelopmental changes that occur during adolescence and have significant 
correlates.  Functional neuroimaging methods are able to detect the functional 
connectivity between brain regions. Functional Near-Infrared Spectroscopy (fNIRS) is an 
approach that has great promise.  
Functional Near-Infrared Spectroscopy (fNIRS) 
 fNIRS is a non-invasive, functional neuroimaging technique that infers changes in 
neural activation via changes in oxygenation levels and blood flow in the brain. When 
neural activity increases in response to a task there is an increase in the cerebral blood 
flow (CBF) to the brain region involved.  When there is an increase in CBF to an area of 
the brain fNIRS detects an increase in the ratio of oxygenated hemoglobin relative to 
deoxygenated hemoglobin in that region of the brain (i.e., the hemodynamic response) 
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(Tachtsidis & Scholkmann, 2016). More specifically, the fNIRS device emits light of 
varying wavelengths that penetrates approximately one to two centimeters into the 
cerebral cortex. Oxygenated blood (HbO2) and deoxygenated blood (Hb) absorb different 
light wavelengths of electromagnetic radiation. Based upon the properties of the tissue 
the light is then scattered at different rates. The scattered light is then detected by the 
fNIRS device and based upon how much light was absorbed one can infer differences in 
hemoglobin concentration. More specifically, greater light absorption suggests increased 
blood flow to that brain region (i.e. greater deoxygenation) which is thought to reflect an 
increase in neural activity in cortical regions of the brain.     
 Relative to alternative neuroimaging methods, fNIRS has a number of advantages 
(Cui, Bray, Bryant, Glover, & Reiss, 2011). First, compared to fMRI, fNIRS is relatively 
inexpensive and simple to use, making it ideal for longitudinal studies that assess 
treatment effects. Further, motion artifacts are less of a concern with fNIRS making it a 
useful alternative to fMRI among adolescents.  Finally, fNIRS is portable and can be used 
within an office or hospital setting making it a convenient and ecological valid approach 
for clinical populations (Noah et al., 2015).  
 A variety of different analytical methods have been applied to fNIRS data. In 
addition to detecting changes in activation in a given region of the brain, recent studies 
have used fNIRS to explore properties of neural networks in the brain using Complex 
Network Analyses (Fekete, Beacher, Cha, Rubin, & Mujica-Parodi, 2014). Efforts to 
apply functional connectivity analytic methods have been particularly promising.  In 
particular, the properties of resting state networks may provide insights into potential 
biomarkers of substance use disorders as well as associations with EF.  Resting state 
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networks have frequently been studies as potential endophenotypes associated with 
different psychiatric issues. Resting state networks can be studied using a variety of 
different statistical methods. For this study, a graph analytic approach was utilized to 
characterize various topological properties of the fNIRS resting state networks. Graph 
theory is a branch in mathematics concerned with the study of networks. Recent work has 
applied graph theory techniques to structural and functional neural networks (Bullmore & 
Sporns, 2009). Briefly, graphs can be used to describe a complex network by 
characterizing it as a set of nodes or vertices, connected to one another by a subset of 
edges (Bullmore & Sporns, 2009).  Specific topological properties of the graph can then 
be calculated at a global level (the entire network), at a nodal level (properties of a given 
node in the network), and at a modular level (clusters of densely connected nodes within 
the network).   
 Relative to random graphs, graph of brain networks have higher clustering and 
more variable degree centrality at each node (i.e., more variability in the number of 
connections between a given node and the rest of the regions in the network).  Brain 
networks have been found to have high clustering and shorter path lengths, a 
phenomenon referred to as “small worldness”.  Path length and global efficiency are 
measures believed to capture the integrative nature of a network (Papo, Buldu, Boccaletti, 
& Bullmore, 2014).  
 Graph theory analyses have been shown to predict meaningful properties of how 
the brain networks across a range of populations and has been utilized in efforts to 
identify potential endophenotypes that may serve as future treatment targets. In sum, 
fNIRS has the potential to assess changes in the BOLD signal in a given region, as well 
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as, changes in FC between regions of a neural network (M D. Fox & Raichle, 2007; M. 
D. Fox et al., 2005).   
fNIRS and Executive Function 
 fNIRS has been used to explore neurobiological correlates associated with EF.  In 
healthy controls, increased oxyhemoglobin was observed in bilateral DLPFC during 
interference trials of the Stroop task (Schroeter, Zysset, Kruggel, & von Cramon, 2003). 
In a different sample, the switching condition of the Stroop was associated with greater 
activation in bilateral anterior DLPFC and bilateral anterior VLPFC activation (Lague-
Beauvais, Brunet, Gagnon, Lesage, & Bherer, 2013). Further, variability in EF 
performance has been associated with variability in oxyhemoglobin changes during an 
EF task in children, providing further support that changes in EF can be detected with 
fNIRS (Schroeter, Zysset, Wahl, & von Cramon, 2004). fNIRS has also been used to 
explore EF impairments in clinical samples. For example, compared to healthy controls, 
adults with EF impairment (diagnosed with ADHD), exhibit less oxy-hemoglobin 
increases in the ventrolateral PFC during a working memory task (Ehlis, Bahne, Jacob, 
Herrmann, & Fallgatter, 2008).  Finally, fNIRS has been used to improved diagnostic 
accuracy rates (Monden et al., 2015). More specifically, using pattern classification 
methods, neural activation during an inhibitory control task improved diagnostic 
accuracy rates in a sample of children with ADHD and typically developing controls.   
 The clinical applications of fNIRS have only recently being explored. However, 
fNIRS has been shown to be informative in predicting treatment outcomes for EF. For 
instance, fNIRS was used to assess changes in oxyhemoglobin in the PFC following an 
exercise intervention for EFs. Results showed the changes in PFC function explained a 
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significant proportion of the variance associated with EF improvement (Lambrick, 
Stoner, Grigg, & Faulkner, 2016). Lastly, fNIRS has been used to assess the impact of a 
pharmacological intervention on EF. In a sample of individuals with ADHD, 
improvements in performance on a task of inhibitory control (go/no-go task) following 
methylphenidate administration was associated with increased right lateral PFC 
activation (Monden et al., 2012). EFs and PFC function have been examined in SUD 
samples using fNIRS, as well (Monden et al., 2015).  
Prefrontal Cortex and Substance Use  
 fNIRS has been used to detect clinically meaningful differences among 
individuals with SUD. In particular, differences in PFC activation patterns in individuals 
with SUD have been linked to reward processing. For instance, when exposed to drug 
cues, individuals with SUD often exhibit greater PFC activation suggesting increased 
effort needed to respond to cues. For instance, individuals with alcohol dependence 
demonstrated increased activation in the left anterior lateral orbitofrontal (OFC) and 
middle OFC when responding to alcohol cues (Ernst et al., 2014). Craving, an indicator 
of SUD severity, was found to be associated with different PFC activation patterns when 
viewing drug cues. More specifically, in adult smokers increased self-reported craving at 
baseline was correlated with increased activation in the OFC and less activation in the left 
DLPFC during smoking cue exposure (Kroczek, Haeussinger, Fallgatter, Batra, & Ehlis, 
2015). When viewing non-drug related reward cues, however, individuals with SUD 
exhibit a different pattern of activation. For instance, individuals receiving treatment for 
opioid dependence exhibited decreased left ventrolateral prefrontal cortex (VLPFC) 
activation to images of positive social interactions and decreased activation in left rostral 
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PFC/VLPFC, right VLPFC, and left medial rostral PFC in response to appetitive food 
cues (Huhn et al., 2016). Overall, this suggests within individuals with SUD, different 
PFC activation patterns are observed when viewing of reward cues relative to controls.  
 Changes in PFC function while viewing reward cues has been associated with 
markers of treatment success. For instance, greater right DLPFC activation to a drug cue 
was observed in recently detoxified individuals with opioid use disorder compared to 
individuals that underwent opioid detoxification several months earlier(Bunce et al., 
2015).  Similarly, within individuals with a history of alcohol dependence, when viewing 
an alcohol cue, decreased activation in DLPFC and dmPFC was associated with 
increased days of abstinence (Dempsey et al., 2015). Lastly, length of recovery was 
positively correlated with increased oxygenated hemoglobin concentration in the PFC 
among the abstinent group during a fluency task (Dresler et al., 2012). In summary, PFC 
activation during reward processing may be an important marker of SUD and a potential 
biomarker of treatment success.  
Executive Function: Treatment Target for Substance Use Disorder 
 Among adults with a SUD, however, EF is one of the best predictors of relapse. 
Impairments in cognitive inhibition of prepotent responses, and other related executive 
deficits, can lead to lack of control over drug or alcohol use, heightened severity of 
dependence, and poor treatment response (Goudriaan, Grekin, & Sher, 2011; Miller, 
1991; Poling, Kosten, & Sofuoglu, 2007). Among adults with a SUD, those with 
evidence of impaired hot EF, such as increased negative affect (Miller, 1991) and 
affective instability (Nace, Saxon, & Shore, 1986) have increased craving, increased 
SUD severity, and poorer treatment outcomes (H. C. Fox, Bergquist, Hong, & Sinha, 
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2007; Sinha, 2007). Among adolescents, hot EF deficits predict escalated drinking 
patterns and binge drinking, suggesting substances may be used in an attempt to modulate 
negative emotions (Colder, Campbell, Ruel, Richardson, & Flay, 2002). Likewise, 
adolescents are at increased risk for developing a SUD if they exhibit impaired EF (Dom, 
De Wilde, Hulstijn, van den Brink, & Sabbe, 2006; Perry et al., 2011; Squeglia, Jacobus, 
& Tapert, 2009; Wilcox, Dekonenko, Mayer, Bogenschutz, & Turner, 2014) with earlier 
onset of substance use linked to greater EF impairments(Sagar et al., 2015). 
 A recent meta-analysis examined the neuropsychological impairments associated 
with OUD across 14 different cognitive domains (Wollman et al., 2019). The authors 
reported the largest effect size difference (Hedges’ g = 0.970) across studies was for 
complex psychomotor ability, which included Digit Symbol Substitution Test and 
Symbol Digit Modality Test. Further, length of time abstinent was correlated with a 
reduction in the effect size for complex psychomotor ability. However, the authors 
reported the average raw score for individuals with an OUD were within the normal 
range. Additionally, in follow up meta-regression analysis, attention  (Trails A time) 
statistically predicted effect sizes for executive function (verbal fluency, inhibition, 
working memory), and verbal memory.  Among individuals with OUD, differences in 
delay-discounting were observed among individuals that use heroin relative to individuals 
that use prescription opioids (Karakula et al., 2016).  
 EF task performance has been linked to changes in PFC activation among 
individuals with SUD. For instance, compared to healthy controls, individuals with 
alcohol dependence exhibited impaired performance on a fluency task and smaller 
functional activation (oxygenated hemoglobin concentration) in regions of the PFC 
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during the task (Dresler et al., 2012). In a different SUD sample, while performance on a 
fluency task was comparable between an Alcohol Use Disorder (AUD) group and healthy 
control (HC) group, the AUD group exhibited less of an increase in oxygenated 
hemoglobin in the PFC relative to the control group (Schecklmann et al., 2007). 
Differences in neural activation on tasks of hot EF have been observed in SUD as well. 
For example, on the Iowa Gambling task, individuals with polysubstance use exhibited 
decreased bilateral DLPFC activation compared to healthy controls (Hammers & Suhr, 
2010). A few studies have reported increased PFC activity in the absence of performance 
differences in individuals with SUD compared to HC. This effect, may, in part, be related 
to the substance of abuse. Specifically, in studies that included ecstasy use increased 
oxygenated hemoglobin in PFC areas was observed during inhibitory control and fluency 
(Roberts & Montgomery, 2015). In sum, while several fNIRS studies have shown SUD is 
associated with reduced PFC activation during EF tasks, this may be moderated by 
substance of abuse.   
 Reduced PFC activation during EF has also been shown to predict future 
substance use using a correlated methodology, fMRI. For instance, adolescents that later 
went on to use substances exhibited less activation in the ventromedial prefrontal cortex 
(vmPFC) during an inhibitory control task compared to adolescents that did not initiate 
substance use(Mahmood et al., 2013). Likewise, reduced activation in the prefrontal 
cortex during inhibitory control was also associated with later substance use initiation 
among adolescents (Norman et al., 2011). Further, severity of future substance use 
(positive history of black outs associated with drinking) was positively associated with 
reduced activation in prefrontal regions during inhibitory control trials as well(Wetherill, 
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Castro, Squeglia, & Tapert, 2013). Finally, improvements in emotional reactivity 
following a period of abstinence have been observed among adolescents with a SUD, 
suggesting hot EF improvements are associated with recovery as well (Winward, 
Bekman, Hanson, Lejuez, & Brown, 2014). Reduced PFC activation during EF is 
observed in adults with SUD, in adolescents that later develop SUD, and is associated 
with SUD severity among adolescents, suggesting it may be an appropriate target.  
Brain Function During Resting State and Substance Use Disorder 
 Resting state fMRI data provide support to suggest functional connectivity is 
altered in individuals with SUD.  Graph theory analyses have been used to identify 
topological properties of networks associated with clinical variables. For instance, small 
world networks properties have been observed among individuals with SUD that are both 
less efficient and more connected compared to healthy controls (Wang et al., 2015).  
Another study found, relative to controls, individuals with SUD showed increased global 
efficiency and decreased local efficiency (Regner et al., 2016).   
 Resting state fMRI data also suggest reduced PFC function during resting state is 
associated with SUD, as well. Adolescents with a SUD exhibit less activation in 
prefrontal regions of the brain during resting state, including: superior frontal gyri, 
middle frontal gyri, and medial frontal gyri compared to typically developing controls 
(Dalwani et al., 2014). Adolescents that currently used alcohol and adolescents that 
would later go on to use alcohol both showed increased BOLD signal in the frontal cortex 
(among other regions), relative to adolescents that did not use alcohol (Ramage, Lin, 
Olvera, Fox, & Williamson, 2015). Finally, among adolescents with a SUD, abstinence 
from substance use was associated with greater activation in prefrontal regions at rest 
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(Dalwani et al., 2014). Overall, reduced PFC activation during rest is observed in adults 
with SUD, in adolescents that later develop SUD, and is associated with SUD abstinence 
among adolescents, suggesting it may be an appropriate target.  While there are other 
cognitive deficits associated with OUD, the EF deficits are related to clinical issues 
directly and are the most appropriate target. 
 Reduced within-PFC connectivity during rest may also be an important treatment 
target. Reductions in within-PFC functional connectivity (N. Ma et al., 2010; Muller-
Oehring, Jung, Pfefferbaum, Sullivan, & Schulte, 2015) and structural connectivity 
(Huang et al., 2013; W. C. Lin et al., 2012; X. Ma et al., 2015), are both associated with 
poorer EF, have been observed in adults with a SUD compared to healthy controls and 
are associated with higher addiction severity, indicating a possible treatment target. 
Reduced with matter integrity in tracts connecting PFC regions with one another are 
observed in individuals with SUD compared to controls (De Bellis et al., 2008; Jacobus, 
Squeglia, Bava, & Tapert, 2013; McQueeny et al., 2009) (F. Lin et al., 2012) and 
increasing behavioral EF impairments was associated with decreasing within-PFC 
structural connectivity.  Overall, reduced within-PFC connectivity during rest is observed 
in individuals with SUD and is associated with EF in SUD, suggesting it also may be an 
appropriate target. 
MBIs and Improved Executive Function 
  Improvements in performance on neuropsychological tests of EF have been 
observed following a MBI across a range of populations. In healthy adult samples, 
improvements in cool EFs, including sustained attention, inhibitory control, working 
memory, and fluency have been observed after a MBI (Chambers, Lo, & Allen, 2008; 
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Deepeshwar, Vinchurkar, Visweswaraiah, & Nagendra, 2014; Heeren, Van Broeck, & 
Philippot, 2009; Jha, Stanley, Kiyonaga, Wong, & Gelfand, 2010; Moore & Malinowski, 
2009; Mrazek, Franklin, Phillips, Baird, & Schooler, 2013; Slagter et al., 2007; Tang et 
al., 2007; Vega et al., 2014; Zeidan, Johnson, Diamond, David, & Goolkasian, 2010).  
Improvements on tasks of hot EF have been observed in healthy adults following a MBI 
as well, including: affective Stroop, emotional attention network test, and Iowa Gambling 
Task (Ainsworth, Eddershaw, Meron, Baldwin, & Garner, 2013; Alfonso et al., 2011; 
Allen et al., 2012; Ortner, Kilner, & Zelazo, 2007). MBIs have been shown to improve 
performance on hot EF tasks in clinical samples as well (Alfonso et al., 2011; Allen et al., 
2012). In clinical adolescent samples, improvements in cool EFs, including: sustained 
attention, inhibitory control, task switching, and self-reported EF behaviors (Bogels, 
Hoogstad, van Dun, de Schutter, & Restifo, 2008; Himelstein, 2011; Le & Proulx, 2015; 
Leonard et al., 2013), and hot EFs have been observed (Leonard et al., 2013).  The 
persistence of EF gains following MBIs are still being explored and longitudinal studies 
are needed. While there is evidence supporting a dose-response to mindfulness, it is 
unclear how long these changes persist in the absence of continued practice.    
 Further, preliminary results suggest MBI may be helpful for adolescents and 
adults with ADHD (a neuropsychological disorder partly characterized by EF deficits) as 
evidenced by improved measures of EF (Zylowska et al., 2008) and behavior (Haydicky, 
Wiener, Badali, Milligan, & Ducharme, 2012). Improvements in symptoms of inattention 
and hyperactivity have been observed among individuals with ADHD following MBI 
(Bogels et al., 2008; Bueno et al., 2015; van de Weijer-Bergsma, Formsma, de Bruin, & 
Bogels, 2012; Zylowska et al., 2008).  Among adolescents with ADHD, improvements in 
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both self-reported and parent-reported symptoms of ADHD (including EF) were observed 
(van de Weijer-Bergsma et al., 2012; Zylowska et al., 2008).  Among adults with ADHD, 
improvements in self-reported clinical symptoms of ADHD and EF were found 
(Zylowska et al., 2008). In summary, MBI show promise in the treatment of a disorder of 
EF in both adult and adolescent samples.     
MBIs and Changes in Prefrontal Cortex Activity  
 There is preliminary evidence to suggest MBIs may change the pattern of neural 
activation during EF tasks. The improvements in cognitive control associated with a MBI 
have been associated with changes in neural processing in the right prefrontal cortex 
(Deepeshwar et al., 2014). Within a sample of older healthy adults, improvements in EF 
were observed that were associated changes in activation patterns using a different 
neuroimaging technique, EEG.  More specifically, greater right frontal alpha activation 
was observed (Moynihan et al., 2013). Specific to Hot EFs, increased activation of the 
DLPFC was observed during a task of Hot EF (affective Stroop task) (Allen et al., 2012).  
Further, amount of meditation was positively correlated with activation in regions 
including the DLPFC and medial PFC during a Hot EF task (Allen et al., 2012).  Lastly, 
within a clinical sample, following a MBI individuals exhibited greater activation in the 
ventrolateral PFC when processing emotions (Holzel et al., 2013).  However, among 
healthy individuals reduced reactivity to sadness following a MBI was associated with 
increased activation in regions of the ACC, vmPFC, and right superior frontal gyrus 
(Farb et al., 2010). During resting state, greater activation in the left PFC were observed 
in healthy adults following a MBI(Tang et al., 2009). Though preliminary, these results 
provide support for the idea that MBIs alter the way the brain processes emotional states.  
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More specifically, reductions in emotional reactivity may be related to changes in PFC 
recruitment during processing of emotions.  As mentioned earlier, while there is support 
for a dose response to mindfulness, the persistence of changes in the absence of 
continued mindfulness practice is unknown. 
MBIs and Changes in Prefrontal Cortex Structure 
 MBIs have been shown to impact the structure and function of the prefrontal 
cortex, a region of the brain associated with EFs (Funahashi & Andreau, 2013).  For 
instance, in a sample of healthy adults, increased cortical thickness in a cluster that 
included the right inferior frontal gyrus was observed following an eight-week 
Mindfulness-Based Stress Reduction intervention (MBSR) (Santarnecchi et al., 2014).  
Further, increased white matter integrity was observed in the anterior cingulate cortex 
(ACC) (Tang et al., 2010). Specific to functional changes, two studies found increased 
activity in the prefrontal cortex (Davidson et al., 2003; Tang et al., 2009), while a third 
study reported decreased activity following a MBI in bilateral frontal pole of the brain 
(Chen et al., 2015).  Each of these studies utilized a different imaging/analysis technique 
and a different MBI.  Consequently, while it is difficult to make a precise hypothesis 
based on these findings, these results do suggest effects in the prefrontal cortex across 
studies.  
 MBIs have been associated with increased recruitment of regions of the prefrontal 
cortex based on functional and structural connectivity. Improved efficiency within the 
anterior cingulate cortex (ACC) during resting state was observed following a MBI (Xue, 
Tang, & Posner, 2011).  Following a MBI, healthy adults experiencing unemployment 
demonstrated increased functional connectivity between the left DLPFC and a seed 
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within the DMN, the posterior cingulate cortex(Creswell et al., 2016). Increased rsFC 
between the between the DLPFC and the dACC was observed following a MBI(Chen et 
al., 2015). Similarly, within a clinical sample, increased functional connectivity between 
the PCC and bilateral medial PFC was observed following a MBI(Wells et al., 2013).  
Interestingly, greater within PFC functional connectivity (increased fc between right 
dorsomedial PFC to left lateral OFC) was observed in the clinical group but not the 
healthy sample of individuals receiving a MBI, suggesting MBIs may impact functional 
connectivity differently in clinical samples(Chen et al., 2015).  
 Changes within PFC functional connectivity are supported by changes in white 
matter within the PFC observed following a MBI.  More specifically, increased white 
matter integrity was observed in in white matter tracts that connect different regions of 
the PFC and within white matter tracts that connect the PFC inter-hemispherically (Tang, 
Lu, Fan, Yang, & Posner, 2012; Tang et al., 2010).  In sum, MBIs have been associated 
with increased recruitment of PFC at rest based on connectivity measures and increased 
PFC activation during EF. Overall, MBI may improve EF in substance users by 
improving measures of EF and via neurobiological changes within the PFC.  
MBIs and Culture 
 Despite the profound benefits of mindfulness practices on various facets of health, 
including SUD it is important to consider the applicability of a MBI for individuals from 
marginalized populations. The use of mindfulness-based interventions in marginalized 
populations has become a focus in recent years.  A recent study examined self-reported 
engagement in mindfulness related practices and identified potential socio-demographic 
barriers that are worthy of further consideration (Olano et al., 2015). Having more than a 
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high school diploma was associated with increased use of mindfulness practices. Further, 
non-Hispanic whites were more likely to engage in mindfulness practices compared to 
Hispanic and non-Hispanic Black respondents. Further, men were less likely to utilize 
mindfulness practices relative to women.  
 Similarly, there is research that suggests among the more common mindfulness 
interventions, MBSR and MBCT, the vast majority of randomized clinical trials have 
samples that are predominantly white (Waldron, Hong, Moskowitz, & Burnett-Zeigler, 
2018). The authors found only one study specifically targeting a MBI among ethnic/racial 
minority or lower SES samples and that study did not report findings. When examining 
research studies that reported findings for other ethnic groups, 76% of the participants 
reported on were white. Further, across studies, individuals had a higher education than 
the normal population and more than 50% of samples reporting employment status and 
mean income of $40,000 or greater.  Notably, this review did not include MBRP, which 
has more support for use in underserved communities.  
 Preliminary research supports the use of MBRP in ethnic minority populations. In 
a sample of women receiving court referred residential treatment for substance use, 
MBRP was found to be more efficacious than relapse prevention (Witkiewitz, Greenfield 
& Bowen, 2013).  Further, the role of racial/ethnic composition may moderate impact of 
MBRP on specific treatment outcome variables. In particular, MBRP may be more 
effective than RP for preventing heavy drinking days among whites, while among 
racial/ethnic minorities, MBRP may be more effective than RP in preventing drug use 
days (Greenfield et al., 2018).   
Specific Aims and Hypotheses 
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 The primary aim of the study was to assess the feasibility of implementing a 
MBRP within an outpatient substance use and methadone clinic from a 
neuropsychological framework.  As mentioned earlier, a neuropsychological framework 
to mental health can help identify new treatment targets and assess changes in those 
markers over time through the use of neuropsychological assessments, neuroimaging 
methods and self-reported symptoms.  Clinical neuropsychology consistently addresses 
cognitive problems and in conjunction with psychological problems.  SUD, and OUD in 
particular, can be conceptualized as disorders of EF. Given the rates of substance use and 
mental health problems during adolescence in individuals that later go on to develop 
SUDs behavioral interventions that are able to simultaneously treat substance use, 
comorbid psychopathology and EF are needed. MBRP is a MBI with the potential to 
target each of these clinical concerns.  
 Overarching Aim. The current study was a pilot randomized control trial to 
assess the feasibility of implementing a MBRP in an outpatient substance use clinic, 
serving predominantly individuals receiving ORT. Treatment targets and study design 
utilized a neuropsychologically-informed framework.  The study aimed to recruit both 
adolescent and young adult participants.  
 Specific Aim 1.  Assess the feasibility of implementing a MBRP intervention 
study at an outpatient substance abuse treatment clinic providing opioid replacement 
therapy for adolescents and young adults. Examine participation interest and retention 
rates across study and feasibility of study design, including data collection procedures 
and outcome measures.  Exploratory Aim: No hypothesis.  
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 Specific Aim 2.  Examine clinical characteristics of resulting sample at baseline 
and identify potential relationship between baseline factors and retention. Hypothesis 1a: 
Individuals enrolled in the study will demonstrate elevated levels of psychopathology and 
substance use. Hypothesis 1b: Individuals retained will demonstrate less psychopathology 
at baseline relative to individuals that were lost to follow up. 
 Specific Aim 3. Assess EF at baseline and the relationship among specific EF 
measures. Hypothesis 2a: Individuals will demonstrate impaired EF at baseline compared 
to the population mean. Hypothesis 2b: EF measures will be correlated, with higher 
correlations among neuropsychological measures of EF relative to self-reported measures 
of EF.  
 Specific Aim 4. Assess topological properties of fNIRS resting state networks and 
relationship to baseline measures of EF. Hypothesis 3a: Resting state networks will 
exhibit small world properties. Hypothesis 3b: Performance on neuropsychological 
measures of EF will be associated with small world network parameters.  
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METHODS 
 
Experimental Design 
 The study used a single-site, randomized waitlist control study to assess the 
effectiveness of Mindfulness Based Relapse Prevention (MBRP) in adolescents and 
young adults diagnosed with a SUD. Potential participants were recruited from the 
adolescent and young adult clinic at the Addiction and Substance Abuse Program 
(ASAP) at the University of New Mexico.  
 All existing clients expected to continue in treatment for at least another 8 weeks, 
and newly enrolled clients thereafter (ages 14-34) were informed about the study. 
Interested participants were given a copy of the study consent form and a study flyer with 
contact information. Adolescents were encouraged to take the consent form home and 
talk to family members before signing it. All young adult participants (age 18-34) were 
randomized to receive: 1) MBRP, or 2) Waitlist Control and were not blinded to group 
assignment. Participants in the MBRP group received a 4-week MBRP treatment. 
Participants in the WC received treatment as usual during that time.  Both groups 
completed one follow up visit following completion of treatment phase. The WC group 
was offered the MBI after all assessments had been completed.   
Recruitment Procedures  
 Potential participants were recruited from the adolescent and young adult clinic at 
the Addiction and Substance Abuse Program (ASAP) at the University of New Mexico. 
The adolescent clinic at ASAP opened in October 2015 and at the time of our initial 
submission had 30 clients enrolled, ages 14-22 years, meeting criteria for opioid use 
disorder, alcohol use disorder, cocaine use disorder, cannabis use disorder, and 
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polysubstance use disorder. 2-4 clients per week are screened. The clinic reports 85% of 
the patients in the adolescent clinic have been retained in their program for 8 weeks or 
longer. At the time of our submission, the clinic reported 70% of the treatment population 
is receiving Opioid Replacement Therapy (ORT) with the 30% on additional 
psychotropic medications. Per director’s report, adolescents are excluded if a residential 
or higher level of care is warranted based on screening visit at the clinic (i.e., active 
severe suicidal/homicidal ideation, active severe behavioral/aggression issues). Typical 
co-occurring disorders observed at this clinic include: posttraumatic stress disorder, 
major depressive disorder, pervasive developmental disorder, generalized anxiety 
disorder, and panic disorder.  
 In May 2018 the study team was made aware of changes to the clinic that 
impacted recruitment.  The clinical director of ASAP, Larissa Maley, Ph.D., provided the 
study team an update on recent structural changes within ASAP. Per director report, 
adolescents ages 14 to 17 years of age receive treatment within the adolescent clinic at 
ASAP, while young adults, ages 18 years and older receive treatment in the adult clinic at 
ASAP. This decision was made based upon the clinical needs of the population served 
within ASAP. Additionally, per clinic director’s report, the clinic has received an influx 
of individuals under 18 years of age with severe psychopathology that would likely result 
in them being excluded from this study. Consequently, based on these updates to the 
clinic, the clinical recommendations of providers at ASAP, and a reduction in the size of 
the recruitment pool within this age range, adolescents between the ages of 14 and 17 
years interested in participation will be consented and enrolled in an Under 18 MBRP 
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group. They will not be randomized to the waitlist control condition, because it was 
deemed unlikely there would be sufficient sample size to achieve this.  
 Additional inclusion criteria include: current diagnosis of SUD based on the 
Structured Clinical Interview for DSM-V (SCID). Additional exclusion criteria include: 
1) significant impairment of cognition or judgment (as observed by study staff or 
indicated by chart review) rendering the person incapable of informed consent, 2) brain 
injury with loss of consciousness greater than 30 minutes based on Center for Disease 
Control’s definition of moderate to severe TBI, 3) diagnosis of epilepsy (based on chart 
review), 4) active psychosis (determined by both chart review and SCID). Participants 
currently taking prescribed psychoactive medications were not excluded, however, 
participants were stabilized on psychiatric medication, including ORT, prior to 
enrollment in the study.  
Study Intervention and Assessment Procedures 
 The assessment battery (EF, ER, and substance use assessments) were completed 
at baseline and at a follow up visit (following completion of treatment) by trained 
research assistants in quiet rooms designed for testing. The assessment battery took 
approximately 3 hours. Transportation was provided to transport participants between 
ASAP and Center for Psychiatry Research/MRN as needed. As mentioned earlier, 
participants underwent a 30-minute fNIRS scan visit at baseline and at follow up. The 
participant was seated at a desk and the cap of the fNIRS acquisition device was placed 
on the participant’s head. After 2-3 minutes for equipment checks, the experimenter 
administered a seven-minute resting state task.  
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 MBRP. Participants received a condensed version of Mindfulness-Based Relapse 
Prevention an intervention that integrates cognitive-behavioral relapse prevention and 
mindfulness practices (Bowen et al., 2011; Roos, 2019). The study intervention was 
provided over the course of eight bi-weekly sessions (60 minutes each) and followed the 
procedures outlined in the treatment manual(Bowen et al., 2011; Roos, 2019). In each 
session participants were instructed on specific mindfulness practices (e.g. body scan, 
mindful movements) and ways to use these practices during high-risk situations (i.e. 
situations that trigger substance use). Participants were assigned to practice mindfulness 
activities at home between group therapy sessions. All MBRP sessions were provided at 
ASAP in rooms designed for group therapy.  
 Therapist Qualifications, Training, and Supervision. Therapists had at least a 
master’s degree in a related field with clinical experience working with pediatric and 
adult samples. Consistent with prior MBRP studies, therapists were required to read the 
entire therapy manual, attend a basic training in MBRP, and commit to a personal daily 
mindfulness practice (Bowen et al., 2011). Cases were discussed in weekly group 
supervision.  
Assessments 
 Neuropsychological Measures of EF.  Subtests were selected from two different 
assessment batteries: the Delis-Kaplan Executive Function System (D-KEFS) and the 
National Institute of Health (NIH) Toolbox for the Assessment of Neurological and 
Behavioral Function (NIH-TB).  
  The Delis-Kaplan Executive Function System (D-KEFS) is a widely used battery 
of EF tests (Delis, Kaplan, & Kramer, 2001). The D-KEFS was normed on a sample of 
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1,700 children and adults (age 8-89 years) with demographic characteristic consistent 
with the United States population according to the 2000 US census. In particular, the trail 
making test (TMT), Color word Interference and Verbal Fluency tasks are frequently 
used. The TMT was designed to measure different cognitive skills that contribute to 
performance on the more widely known Trail Making Testing with two conditions. TMT 
consists of five conditions that measure, visual scanning, number sequencing, number-
letter switching, and motor speed, respectively.  Verbal Fluency measures fluent 
productivity in the verbal domain across three conditions. On the first condition, the 
individual is asked to say names beginning with a specific letter (Letter Fluency), on the 
second condition the individual is asked to name words from a specific category 
(Category Fluency), and on the third condition the individual is asked to switch between 
saying words from two different categories (Category Switching). Two scores are 
produced from this condition: total number of words and accuracy in switching.  Color-
Word Interference is similar to the Stroop test. The individual is asked to name color 
patches in condition 1, read the color names printed in black ink on the second condition, 
and then on condition 3, the participant must name the color of the ink that color words 
are printed in (e.g., the individual must say “red” when reading the word “blue” which is 
printed in red ink). The fourth condition adds a switching condition, where the individual 
is instructed to shift back and forth between naming the ink colors and reading the color 
words.  Internal consistency across the select subtests varies. Internal consistency from 
TMT for combined number and letter sequencing composite ranges from .60 to .81 . 
Verbal fluency internal consistencies by condition: Letter Fluency .68-.90, Category 
Fluency .53 to .76, Switching Total Correct .37 to .68, and Switching Accuracy .51 to 
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.76.  Internal consistency for Color Word Interference for combined color naming and 
word reading composite score ranges from .62 to .86.  Correlations between tasks on the 
D-KEFS are relatively low, while correlations among measures from the same task are 
higher.  
 The National Institute of Health (NIH) Toolbox for the Assessment of 
Neurological and Behavioral Function (NIH-TB) was developed to measure four 
domains: cognition, motor function, sensation and emotion (Weintraub et al., 2013; 
Weintraub et al., 2014). Specific to the Cognition Domain, the toolbox includes several 
tests of EF that can be used to measure the construct across the lifespan at multiple time 
points. The Cognition Battery covers seven cognitive subdomains, defined by the creators 
as: Executive Function, Episodic Memory, Language, Processing Speed, Working 
Memory and Attention.  The tasks were normed on a sample of 476 individuals ages 3 to 
85 years. Three levels of education and 3 racial/ethnic categories were included. The 
Toolbox contains four measures of EF that map well onto Miyake and Friedman’s model 
of EF.  
 The NIH-TB Flanker Inhibitory Control and Attention Task is a variant of the 
Eriksen flanker task used on the Attention Network Test.  On each trial, the individual is 
presented with an arrow in the center of the screen, flanked by similar arrows on either 
side of it. On congruent trials, the center arrow and the flankers are pointing in the same 
direction. On incongruent trials, the flankers are pointing in the opposite direction as the 
center arrow. The participant must respond to indicate the direction of the center arrow as 
quickly as possible. This task measures one’s ability to inhibit attention to visual 
distractors. This task takes approximately 4 minutes to complete and consists of 40 trials.  
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 The NIH-TB Dimensional Card Sort Test measures shifting ability. Individuals 
are presented with a target image and then asked to match it to one of two stimuli based 
on either shape or color. The word “color” or “shape” appears on the screen to indicate 
which category to use. This task takes approximately 4 minutes to complete and consists 
of 40 trials.  
 The NIH-TB List Sorting Working Memory Test was adapted from the Mungas’ 
List Sorting task. Participants are presented with a series of stimuli visually and orally, 
one at a time. In the first condition, participants must then repeat back the items in order 
of smallest to largest.  While all the stimuli are from the same category in the first 
condition, in the second condition, participants are given stimuli from two different 
categories. They are then asked to repeat back the items from smallest to biggest for the 
first category and then the second category. The number of stimuli presented increases 
across trials.  The test is discontinued when an individual fails two trials of the same 
length. This test takes approximately 7 minutes to administer.  The  NIH-TB Pattern 
Comparison Processing Speed Test is based on the Salthouse’ Pattern Comparison Task. 
On this task, participants are asked to pick if two images or patterns are the same or 
different. This task takes approximately 3 minutes to administer and the score is the total 
number of correct items (up to 130) finished in 90 seconds. 
 Self-Report Measures of EF.  Barrett Impulsiveness Scale (BIS-11) is a 30-item 
self-report measure of impulsivity.  Internal consistency coefficients range from .79 in a 
sample of patients receiving treatment for substance use to .82 for undergraduates and .83 
for psychiatric samples (Patton, Stanford & Barratt, 1995).  White Bear Suppression 
Inventory (Wegner & Zanakos, 1994) is a 15-item questionnaire measure of thought 
 36 
suppression. Internal consistency coefficients ranged from .87 to .89 and reliability 
ranged from .92 to .69. The Difficulties in Emotion Regulation (DERS) is a 36-item self-
report measure of self-reported emotion regulation problems (Gratz & Roemer, 2004). 
Internal consistency ranged from .82 to .94 (Hallion, Steinman, Tolin, & Diefenbach, 
2018).  
 Mood and Anxiety Measures. Perceived Stress Scale (PSS) is a 10-item scale 
that measures the extent to which events in one’s life are perceived as stressful. Internal 
consistency ranged from .84 to .86 and test-retest reliability ranged from .55 to .85 
(Cohen, Kamarck, & Mermelstein, 1983).  The Penn State Worry Questionnaire (PSWQ) 
is a 16-item measure of frequency and intensity of worry (Meyer, Miller, Metzger, & 
Borkovec, 1990). It has good internal consistency (.88 to .95) and good test-retest 
reliability (.92). The Beck Depression Index-Two (BDI-2) is a 21-item self-report 
measure of presence and severity of symptoms of depression. It takes approximately 10 
minutes to complete. Internal consistency coefficients range from .73 to .92 and internal 
consistency (alpha coefficients from .86 to .81) (Beck, 1988). State Trait Anxiety Index 
(STAI) is a 40-item questionnaire that assess both state anxiety and trait anxiety 
symptoms (Spielberger, 1983). Internal consistency coefficients range from .86 to .95, 
with test-retest reliability coefficients from .65 to .75  (Spielberger, Gorsuch, Lushene, 
Vagg, & Jacobs, 1983). 
 Substance Use Measures. The Form 90 is a semi-structured interview that 
captures substance use and treatment use in the past 90 days.  The Alcohol & Drug 
Consequences Questionnaire is a 28-item questionnaire created to capture motivations to 
make changes in substance use behaviors and motivations to stay the same.  A Visual 
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Analogue Scale for craving was administered where individuals mark on a 100-
millimeter line the extent of craving they feel at that moment for the drug of abuse, 
ranging from 0 to 100.  
 Mindfulness Measures. Mindful Attention Awareness Scale (MAAS) is a 15-
item questionnaire created to measure receptive a core component of trait mindfulness: 
the awareness and attention to present moment experience. Internal consistency was .89 
(MacKillop & Anderson, 2007). The Kentucky Inventory of Mindfulness Skills (KIMS) 
is a 39-item questionnaire that assesses four mindfulness skills: observing, describing, 
acting with awareness, and accepting without judgment (Baer, Smith, & Allen, 2004). 
Internal consistency coefficients range from .76 to .91 and test-retest reliability ranges 
from .65 to .86. 
 Additional Measures. Substance Use and Psychotic and Associated Symptoms 
sections of the Structured Clinical Interview for DSM-V (SCID), CASAA Demographic 
Questionnaire, and an experimental hot EF task, an emotional go-no-go task were 
administered. Specific to the hot EF task, on each trial participants’ were presented with 
one of two shapes (circle or square) and instructed to only respond (i.e., hit the space bar 
on a laptop) when they saw one of the two shapes. Participants were presented with 
neutral or distressing images in between each trial. 
Neuroimaging Acquisition and Analyses 
 NIRS data was collected using the NIRScoutX 64x32 imager system produced by 
NIRSX Medical Technologies, LLC. A sampling rate of 2.60 was utilized based upon the 
number of channels.  A NIRX cap was utilized and a user-defined montage was designed 
based on previous studies examining whole-head resting state scans using NIRS (Geng, 
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Liu, Biswal, & Niu, 2017; Novi, Rodrigues, & Mesquita, 2016). The montage was 
comprised of 46 optodes: 22 source optodes and 23 detector optodes, for a total of 80 
identified potential channels out of 552 possible channels. The montage created was 
intended to capture cortical activity in frontal, occipital, temporal and parietal cortices. 24 
channels covered the frontal lobes. The EEG 10-20 coordination system was used to 
support accurate placement of optodes. Per NIRX instructions, all caps placed on 
participants’ heads were aligned with the CZ point as measured on each individual 
(measure inium to nasium).   
 Raw data was converted to nirs format using a modified version of the NIRx2nirs 
script running in matlab that utilizes functions from Homer2 toolbox for nirs analysis 
preprocessing.   Data preprocessing involved 3 steps to reduce the “noise” in the data: 
truncate the time series to select appropriate time intervals, removal of data artifacts, i.e., 
“steps” and “spikes”, and filter frequency bands that are irrelevant to the data. Several 
different frequency bands are available for use. A low pass frequency filter removes all 
data above a predefined threshold or time scale, and is often used to de-noise the data. A 
high pass frequency filter is used to de-trend the data. For the present analyses, a band 
pass filter was selected as it serves to filter out both high and low frequency data and is a 
combination of the high and low pass filters.  Parameters for Hb-concentration 
calculations were selected and used to compute the hemodynamic states making use of 
the Beer-Lambert Law. 
 Preprocessing was completed using the FC-NIRS toolbox. All raw data went 
through the following processes: Intensity2OD, OD_bandpassFilter, OD2Con, Detrend, 
MotionCorrect_Spline, and MotionCorrect_CBSI. Cut time was the only step removed 
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from the default setting and the two motion correction methods were added: a spline 
interpolation method and a correlation-based signal improvement (CBSI) approach.  
 Resting-State Task. Prior to initiation of the task, participant were told they 
would be asked to sit quietly for eight minutes with their eyes closed. They were 
instructed to do their best not to move during the task. Following a 30 second baseline, 
participants were then instructed to “close your eyes, think about nothing in particular”.  
 Functional Connectivity Analysis. Functional connectivity was calculated first 
using the whole-brain correlation approach. Relative to a seed-based approach, the whole 
brain approach to connectivity calculates the strength of the correlation between brain 
regions. Pearson correlations between channels were generated.  Graph metrics were 
generated using FC-NIRS toolbox, which utilizes the Gretna toolbox. The Gretna toolbox 
uses scripts and functions from the Brain Connectivity Toolbox (BCT). BCT is a matlab 
toolbox that analyzes complex brain connectivity networks using graph theory. The 
methods in BCT have been applied to both structural and functional connectivity analyses 
across a range of different imaging methods including fMRI, DTI, and EEG. When 
applying graph metrics to fnirs data, each channel is a vertice and the connectivity 
between two channels is an edge(Xu et al., 2015).  The FC-NIRS toolbox performs graph 
analyses on the HbO, HbR and HbT maps separately.  
 Global and nodal topological features of the network are calculated via the FC-
NIRS toolbox and compared to random networks (Wang et al., 2015).  Gretna uses the 
Markov-chain algorithm to generate random networks. Using this approach, random 
networks were generated (1000) with the same number of nodes, edges, and degree 
distribution. Binary networks were examined using a sparsity threshold (0.1 to 0.5 with 
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0.01 intervals). Five small world properties were calculated (clustering coefficient, path 
length, gamma, lambda, and sigma), two measures of efficiency (global and local 
efficiency), and one nodal measure (degree centrality) were calculated. The Area under 
the curve (AUC) was for network measures as well.  
 Small worldness was measured using five different, but related variables. The 
clustering coefficient of the network (Cp) and the shortest path length of the network (Lp) 
were generated for each participant and at the group level. Gamma was calculated, which 
is the ratio of Cp and the mean value of Cp from the random network. Lambda is the ratio 
of Lp and the mean value of Lp from the randomized network. Sigma is the ratio of 
Gamma and Lambda. The Area Under the Curve (AUC) was generated for Cp and Lp to 
get a scalar variable for these variables that is not impacted by threshold selection.  
Statistical Analysis 
 Data analyses for specific aims 1 through 3 were conducted using IBM SPSS 
Version 26.  For specific Aim 4 the following programs were used: FC-NIRS toolbox and 
Gretna toolbox that use scripts and functions from the Brain Connectivity Toolbox (BCT) 
run in Mathworks (MATLAB 2019a). 
 Specific Aim 1.  Retention rates and frequency analyses were performed. 
Descriptive statistics were performed on baseline characteristics.   
 Specific Aim 2.  Descriptive statistics were performed on symptom measures. 
Mann-Whitney U Tests were performed to examine differences between individuals that 
completed follow up relative to those that did not on 11 baseline variables. Fisher’s Exact 
Tests were performed to assess differences in 7 categorical baseline variables among 
individuals that completed follow up and those that did not.  
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 Specific Aim 3.  Spearman correlation coefficients were calculated to examine 
relationships between EF tests (4 scores from the NIH toolbox, 13 scores from D-KEFS, 
and 3 scores from self-report measures) at baseline. Single sample T-tests were 
performed to examine differences between population mean and study sample mean for 
the EF scores (4 scores from the NIH toolbox, 13 scores from D-KEF).   
 Specific Aim 4. Functional connectivity matrices were generated for resting-state 
fNIRS networks using Pearson correlation coefficient. Topological properties of resting 
state networks were generated across multiple sparsity thresholds and using Area Under 
the Curve scalar values.  Spearman correlation coefficients were calculated to examine 
relationship between 20 EF variables  (17 neuropsychological scores and 3 self-report 
scores) and 7 network measures. 
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RESULTS 
 
Specific Aim 1: Feasibility Assessment 
 Recruitment Phase. The treatment protocol was presented at staff meetings for 
treatment providers in the general clinic and within the STAR program team. Based upon 
recommendations from treatment staff members, participants were recruited from the 
clinic on a variety of days and times.  Clients at the clinic receive medication on different 
schedules based upon treatment phase. Thus, while some clients present to the clinic 
daily to receive medication, others are able to take home several doses at a time. With 
extended compliance of treatment demands, clients may earn up to a 30-day supply of 
medication to take home. Thus, recruitment efforts were coordinated to ensure the widest 
net was cast within the adult clinic (age 18 and older).  Based upon staff 
recommendations, additional recruitment efforts were conducted in early morning hours 
(6:00 am to 11:00am).   
 Efforts to recruit from the STAR program were similarly coordinated based upon 
client flow in the clinic. Treatment staff recommended efforts to recruit from the 
adolescent clinic be scheduled in afternoons. The flow of adolescent patients to the ASAP 
clinic during the recruitment phase of the study (May 2018 through July 2018) were 
significantly fewer than originally predicted (0 to 3 adolescents presenting to the clinic on 
any given day). As previously mentioned, the psychopathology among the adolescents 
was more severe than had been previously expected during initial meetings with the staff.   
Flyers were also placed throughout the clinic with the study contact number. 
Additionally, on recruitment days, potential participants were offered flyers and later a 
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recruitment table was set up.  Overall, 78 participants indicated interest in participating in 
the group. Of those, at least 45 were within the targeted age range for the young adult 
group.  One potential participant under 18 years of age indicated interest but was unable 
to attend due to transportation. Four individuals age 18 to 20 years of age indicated 
interest, of those two were disqualified by ASAP staff, one declined to participate due to 
scheduling conflicts and one declined to participant for personal reasons.  
 Qualitatively, it was noted interested participants verbally expressed interest in 
the neuroimaging component of the study. Compensation was very limited and 
participants interested in the treatment verbally expressed motivation based on the 
treatment opportunity and research experience.  Per staff and patient report, group 
interventions were relatively new to the clinic, which likely impacted recruitment.  Over 
the course of the study increased referral from staff and referral among patients were 
helpful.   
 Retention. Throughout the course of the study, retention was a significant 
challenge. At each phase of the study participants were lost to follow up. 20 Participants, 
six men and fourteen women, were consented to the study. Nine participants were 
Hispanic, one participant was Native American/Alaska Native, and ten participants were 
white. Participants averaged 28.90 years of age  (SD = 3.26, range 23-34).  Of those, 16 
participants completed screening visits.  One participant consented to treatment but was 
excluded prior to screening visit based on ASAP staff personnel suggestion. Two 
participants that consented to treatment declined scheduling a screening visit due to 
schedule changes and/or personal reasons, and one participant was lost to follow-up after 
the consent visit. 
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 During the screening process, two participants were excluded due to active and 
uncontrolled psychosis, and one participant was excluded due to psychosis, severe 
depression, severe suicidal ideation, and a history of aggressive behaviors associated with 
psychotic episodes.  13 participants completed baseline assessment visit and were 
randomized to treatment. 
 Treatment Exposure and Follow-Up.  Six participants were randomized to 
waitlist and seven participants were randomized to the intervention condition. Among 
individuals randomized to receive treatment (intent to treat), 6 of the 7 attended two or 
more sessions. One participant declined to participate in treatment following 
randomization and received 0 sessions. Of those that attended treatment, they received an 
average of 4.5 sessions of treatment. Six of the thirteen participants (3 per group) 
completed the follow up visit.  Please see Figure 1 for recruitment and retention outline.  
 There were no adverse events reported. Several participants underwent changes to 
psychiatric medications during the study. Of the 13 individuals randomized to treatment, 
two participants received an administrative discharge from the ASAP treatment program, 
one participant discontinued services at the treatment program, and one participant was 
lost to follow up by all treatment staff following a relapse.  Additional issues impacting 
retention: included lack of transportation to ASAP clinic, lack of stable means of 
communication with study team, and scheduling conflicts associated with school/work.  
This is a significant limitation of the study that will be explored further in the discussion 
section.   
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75  initiated screening process 
20 consented  
16 completed screening visit 
13 completed baseline visit 
6 received 2 MBRP or more sessions 
  
1 declined all MBRP sessions 
Waitlist Group 
  
 
3 completed follow up visit 
 
4 lost to follow up 
3 completed follow up visit 
 
3 lost to follow up 
3 excluded for  
psychiatric condition 
3 lost to follow up 
 
1 excluded based 
on clinical judgment 
of clinic staff 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flowchart for study recruitment and retention. MBRP, Mindfulness-Based 
Relapse Prevention.  
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 Feasibility of Study Design and Procedures. Three research assistants were 
trained to assist in recruitment to enable recruitment to target both the STAR clinic and 
adult clinic simultaneously. Consistent research study staff presence helped address 
frequent no shows. For instance, on days multiple research team members were present, it 
was possible to schedule multiple potential participants or meet with “walk in” 
participants.  Given the culture of “walk-in” health care available at the clinic, when 
possible, it was beneficial for study staff to be available to meet with walk-in study 
participants or participants that wished to reschedule.  Qualitatively, it was noted 
potential participants at the clinic often engaged with study staff on multiple occasions 
before requesting additional information about the study.   
 Flexibility around timing of study procedures also appeared important. For 
instance, on several occasions staff members met with interested participants for the 
consent visit over multiple sessions.  Since there was no permanent or semi-permanent 
office space consistently available within the clinic, it was important to have all materials 
needed on hand for the different stages of recruitment.   Notably, the baseline procedure 
involved neuroimaging and neuropsychological testing equipment and was completed at 
a different location. Likely, if baseline and follow up visits could have been completed at 
the clinic in semi-permanent space, this might have increased follow up rates.  Finally, 
the intervention was successfully implemented to participants in the treatment group. 
Thus it was feasible to implement an empirically supported intervention within a 
methadone clinic.  
 Feasibility of Study Measures. Regarding measures of EF, both the 
neuropsychological measures and self-report measures were successfully administered.  
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The experimental hot EF task was administered to a subset of the participants. 
Qualitatively, the task was time consuming (approximately, 15 minute minimum). It was 
the last EF task administered to prevent a carry over effect to cool EF tasks. While it was 
tolerable for most participants, based on clinical judgment it was not administered to 
several participants.  Again, the presence of multiple study staff members significantly 
expedited the set-up time need for NIRS.  Similarly, on occasions when multiple 
participants arrived at the clinic together, when multiple staff members were present, the 
process was faster.  Qualitatively, it was noted that participants expressed interest in 
NIRS and all participants requested pictures or video of their brain scans. FNIRS does 
enable immediate display of activation on a glass brain, which makes it a more 
reinforcing experience for participants. Several analysis toolboxes have been created for 
fNIRS, with varying complexity. FC-NIRS is relatively, user-friendly program with 
relatively fast computation time. While some tasks could be batched during the analyses, 
future efforts to batch preprocessing steps would likely speed up the analyses further.  
While the GUI interface was user friendly, many of the preprocessing steps (e.g., 
calculation of Hb-concentrations, application of frequency filters, truncation of time 
series) were performed for each participant separately.  Thus, for each participant, the 
user must manually select the input and output file locations, select the desired frequency 
filters, and enter the time series to be selected.  While this was quite feasible with a small 
sample size, it would be more taxing with larger sample sizes. Automating this process 
through scripts or via a GUI designed to run batch jobs would be helpful. 
 Regarding measures of mood, there was some redundancy across measures. 
Elimination of some measures would likely shorten the process. Likely, one of the two 
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mindfulness measures would likely be sufficient. While a heterogeneous sample in terms 
of substances of abuse may reflect more “real world” clinics, often measures of substance 
use and measures of SUD outcome, are designed for a single substance of abuse. 
Assessment measures designed to capture multiple substance uses would likely be 
helpful.  Finally, measures specific to ORT would perhaps be useful. The Drug Use 
Consequences form likely was not appropriate for participants at all stages of treatment 
as it captures consequences and benefits for quitting rather than maintaining the current 
behavior change.   Measures of motivation and readiness to change might be particularly 
useful for this sample. Finally, measures of functional outcome would likely be useful to 
capture meaningful change in the context of ORT.   
Specific Aim 2a: Clinical Characteristics of Sample 
 Demographics. Participants were nine women and four men with DSM-5 
substance use disorder.  Three participants were Hispanic, one participant was Native 
American/Alaska Native, and nine participants were white Non-Hispanic.  Mean age was 
28.28 (SD 2.6, range 25-33). Participants averaged 12.4 years of education (SD 2.2, range 
8-16). One participant reported English as a second language and three participants 
reported speaking a second or third language. Three participants reported part-time 
employment, nine participants were unemployed, and one participant was receiving 
disability. One participant was living in his/her own apartment, one participant was living 
in a transitional substance use treatment facility, and eleven participants were living with 
relatives.  None of the participants reported experiencing homelessness and none of the 
participants reported being court-ordered to treatment. 
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 Baseline Characteristics.  Of the 13 participants that completed the baseline 
visit, nine participants presented with opioid use disorder, one participant with alcohol 
use disorder, one participant with inhalant use disorder, one participant with cannabis use 
disorder, and one participant with methamphetamine use disorder.  All but one of the 
participants was being treated with MAT.  Of the 12 individuals prescribed MAT, seven 
participants were prescribed methadone, three were prescribed buprenorphine, and two 
were prescribed naltrexone.  In total, 12 of the 13 participants reported use of two or 
more substances when using their drug of choice. Nine of the 13 participants reported 
concurrent abuse of opioid and stimulants.   
 Psychiatric History and Present Level of Care and Substance Use Treatment.  
Mean number of inpatient psychiatric hospitalizations was 1.38 (range 0-6) and seven of 
the 13 participants had attempted suicide one or more times (range 0-6).  A significant 
proportion of the sample (92%) reported one or more co-morbid psychiatric diagnoses 
and nearly three quarters of the sample (76.9%) were taking one or more psychiatric 
medications (range 0-5 psychiatric medications).  In the 90 days prior to baseline 
assessment, mean number of outpatient therapy sessions was 11.61 (range 3-28; SD = 
6.55).  Lastly, mean age of first psychiatric problems was 15.15 (range 10-26, SD = 
5.28), mean age of first alcohol use was 15.83 years (SD = 3.29) and mean age of first 
substance use was 14.84 years (SD = 2.54), while mean age of first substance use 
treatment was 22.76 years of age (SD = 3.91).  Please see Table 1 for additional 
information on psychiatric and substance use history.   
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Table 1 
Sample Demographics 
Variable 
 
 
RTF  
(n = 6) 
LTF  
(n = 7) 
Total  
(N = 13) 
U 
 
p-value 
 
Age, years 
    Mean (S.D.)  29.5 (2.95) 27.4 (2.25) 28.38 (2.69) 13 0.085 
Sex (M, F) 1, 5 3, 4 4, 9 - 0.559 
Ethnicity 
    Hispanic 
  
2 1 3 - 0.559 
     
   Native American 0 1 1   
   Non-Hispanic White 
 4 5 9   
Ethnic Minority Status 
2 2 4 - 1.0 
MBRP Group  
3 4  7 - 1.00 
Total Study Visits 
7.5 (3.99) 4 (1.29) 5.6 (3.28) 9 .08 
Employment Status  
   (Number Unemployed) 4 5 
 
9 
 
- 1.0 
Education 
 11.5 (2.81) 13.14 (1.07) 12.38 (2.14) 10 0.198 
Living with Relatives 
Transitional Living 
Living Independently 
 
5 
1 
0 
5 
0 
2 
10 
1 
2 
- 0.462 
Age of First Mental 
Health  
   Mean (SD) 
14.83 
(3.66) 15.43 (6.68) 15.15 (3.3) 18.5 .720 
Age at First Drug use 
   Mean (SD) 
15.83 
(2.32) 14 (2.58) 14.85 (2.54) 11 .15 
Age Substance use 
treatment 
  Mean (SD) 
23.17 
(4.36) 22.43 (3.82) 22.77 (3.92) 20 .886 
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Note: RTF, Return To Follow Up; LTF, Lost to Follow Up; M, male; F, female; S.D., 
standard deviation. Significance levels were determined by Mann-Whitney U test and 
Fisher’s Exact Test.  
 
 
  Measurements of Substance Use.  Participants reported a high level of 
perceived benefit associated with changing/maintaining reduction in substance use (M = 
4.47, SD = 0.58), and a relatively lower level of perceived cost associated with this 
change (M = 2.36, SD = 0.73). Perception of current level of craving was also measured 
using a visual analogue scale (M = 21.75, SD = 21.88). In the past 90 days, roughly one 
third of participants (38%) reported use of substance of abuse (days of use: M = 12.90), 
and about three quarters of the sample (76.9%) reported use of another substance of 
abuse (days of use: M = 43.4). Abuse of prescription medication was reported by at least 
two participants. Over half the sample (61%) reported use of marijuana at baseline.  
Finally, all but one participant reported some tobacco use in the past 90 days. Please see 
Tables 1 and 2 for additional information on substance use reported at baseline. 
 
Number of Suicide 
Attempts 
Mean (SD) 
2.6 (2.3) 1.17 (1.94) 1.81 (2.14) 8.5 .219 
Inpatient 
Hospitalizations 2 (2.76) 0.43 (0.53) 1.15 (1.99) 16.5 .477 
Outpatient Therapy Days 11.5 (4.51) 11.71 (8.3) 11.62 (6.55) 18.5 .720 
Drug of Abuse Days 0.33 (0.82) 23.71 (30.48) 12.92 (24.74) 11.5 .122 
Other Drug Days 19 (35.05) 64.42 (43.67) 43.46 (44.95) 11.5 .151 
Number of Psych 
Medications 3.5 (1.52) 1 (1.15) 2.15 (1.82) 4 .013 
Discontinued at Clinic 0 5 5 - .021 
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Table 2 
Baseline Self-Report Measures 
Measure TOTAL M (SD) 
RTF  
M (SD) 
LFT 
M (SD) U P 
BDI-2 19.69 (13.07) 27 (15.06) 13.43 (7.3) 9 .086 
PSS 21.92 (6.92) 22.83 (8.04) 21.14 (6.36) 14 .313 
PSWQ 57.15 (11.25) 61.5 (8.76) 53.43 (12.42) 13 .252 
STAI-S 37.67 (9.72) 42.8 (13.10 34 (4.58) 12.5 .414 
STAI-T 46.33 (12.07) 54 (13.27) 40.86 (8.11) 7 .088 
KIMS-Total 120.38 (15.06) 114.17 (17.06) 125.71 (11.8) 12.5 .221 
MAAS 3.78 (0.88) 33.50 (6.12) 45.14 (9.77) 6 .031 
VAS Craving 21.75 (21.88) 24.00 (24.31) 19.5 (21.22) 15.5 .688 
ADCQ 
benefits 4.47 (0.58) 4.34 (0.72) 4.58 (0.46) 16.5 .517 
ADCQ costs 2.36 (0.74) 2.40 (0.48) 2.33 (0.94) 16.5 .52 
BIS-11 67.92 (8.89) 69.5 (10.13) 66.57 (8.24) 16.5 .52 
WBSI 53.54 (7.62) 53 (9.44) 54 (6.43) 20.5 .943 
DERS 94.31 (23.0) 106 (23.55) 84.2 9 (18.50) 10 .116 
Note: BDI, Beck Depression Inventory; PSS, Perceived Stress Scale; PSWQ, Penn State 
Worry Questionnaire; State Trait Anxiety Inventory-State, STAI-S; STAI-T, State Trait 
Anxiety Inventory-Trait; KIMS-T, Kentucky Inventory of Mindfulness Skills- Total; 
MAAS, Mindful Attention Awareness Scale; VAS, Visual Analogue Scale; ADCQ, 
Alcohol and Drug Consequences Questionnaire; BIS, Barrett Impulsivity Scale; WBSI, 
White Bear Suppression Inventory, WBSI; DERS, Difficulties in Emotion Regulation 
Scale; RTF, Return To Follow Up; LTF, Lost to Follow Up; M, mean; S.D., standard 
deviation. Significance levels were determined by Mann-Whitney U tests and Fisher’s 
Exact Test. 
 
 Measurements of Mood, Anxiety and Mindfulness. At a group level, 
participants reported elevated levels of depressed mood on the BDI-2 (M = 19.69, SD = 
13), with six reporting moderate or greater depressed mood and seven reporting minimal 
to mild depressed mood.  Regarding anxiety, participants reported high levels of trait 
worry (PSWQ: M = 57.15, SD 11.25), and elevated levels of state and trait anxiety 
(STAI-T: M = 46.8, SD 12.5; STAI-S: M = 37.6, SD 9.7).  Participants also reported 
experiencing an elevated number of events perceived to be stressful over the past month 
(PSS: M = 21.9, SD = 6.9).  Regarding self-reported mindfulness, on the Mindful 
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Attention Awareness Scale (MAAS) scores were comparable to that reported by a college 
student sample (M = 3.78; SD = 0.87). On the KIMS Total Mindfulness score was 120.38 
(SD = 15.05).  Please see Table 2 for additional information on symptoms reported at 
baseline.  
Specific Aim 2B: Examine Correlates Between Retention and Baseline Correlates 
  Using Fisher’s Exact Test, follow up attendance did not differ by gender, 
(p = .559); Hispanic ethnicity (p = .559); ethnic minority status (p = 1.0); employment 
status, (p = 1.0). No differences in age at baseline (U = 13; p = 0.245), age at first 
substance use treatment encounter (U = 20; p = 0.886), suicide attempts (U = 8.5; p = 
0.219), age at first mental health encounter (U = 18.5; p = 0.720), number of inpatient 
hospitalizations (U = 16.5; p = 0.477), age first drug use (U = 11; p = 0.150), number of 
outpatient therapy days at baseline (U = 18.5; p = 0.720), number of days substance of 
abuse was used (U = 11.5; p = 0.122), or number of days other substances used (U = 
11.5; p = 0.151).  Number of psychiatric medications (U = 4; p = 0.013) at baseline was 
significant, with greater psychiatric medications associated with greater likelihood of 
completing the follow up visit.  
 Consistent care within the treatment facility was an important factor. Four of the 
participants lost to follow up were no longer receiving care at the facility at the time of 
the follow up visit.  Follow up attendance was related to continued care at the facility at 
the time of the follow up visit (p = .021, Fisher’s Exact Test).  Please see Table 1 and 2 
for complete list of baseline variables examined and corresponding significance values.  
Aim 3: Relationship Measures of EF 
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 Neuropsychological and Self-Report Measures of EF at Baseline.  At a group 
level, when compared to normative data, participants scored in the average range on all 
measures of EF, with the exception of PC (M = 74.95, SD = 15.17), which was below the 
general population, t(12) = -5.95, p = 0.000, 95%CIs [-34.21, -15.87]. More specifically, 
participants in the study scored between the 21st and 60th percentile on measures of 
executive function, with the exception of one measure of processing speed, which was at 
the 5th percentile. However, when the number of impaired EF scores was examined, all 
participants had one or more EF scores 1 or more standard deviations below the 
normative mean (16th percentile). Nine of the 13 participants had one or more EF scores 2 
standard deviations below the mean or lower (2nd percentile).  Regarding self-reported 
EF, participants reported elevated levels of emotion dysregulation (DERS: M = 94.31, 
SD = 23), impulsivity (BIS: M = 67.92, SD = 8.89), and an elevated tendency to suppress 
thoughts (WBSI: M = 53.53, SD = 7.6). EF performance of the sample is provided in 
Table 2 (self-report measures) and Table 3 (neuropsychological measures). 
Table 3 
Neuropsychological Measures of Executive Function 
Score M SD Comparison 
Value 
Mean 
Difference 
95% CI t df P value 
Trails 1 9.85 2.30 10 -0.24 [-1.55, 1.24] -0.24 12 .814 
Trails 2 9.00 3.24 10 -1.11 [-2.96, 0.96] -1.11 12 .288 
Trails 3 8.38 4.46 10 -1.31 [-4.31, 1.08] -1.31 12 .216 
Trails 4 8.92 3.35 10 -1.16 [-3.10, 0.95] -1.16 12 .269 
Trails 5 10.85 1.68 10 1.82 [-0.17, 1.86] 1.82 12 .094 
Letter Fluency 9.08 3.69 10 -0.90 [-3.15, 1.30] -0.90 12 .384 
Category Fluency 9.69 3.12 10 -0.36 [-2.19, 1.58] -0.36 12 .728 
Switching Fluency 8.92 3.01 10 -1.3 [-2.90, 0.74] -1.29 12 .222 
Switching Accuracy 9.08 2.78 10 -1.2 [-2.60, 0.76] -1.2 12 .255 
Color Naming 8.23 3.27 10 -1.95 [-3.75, 0.21 -1.95 12 .075 
Color Word 9.15 2.64 10 -1.16 [-2.44, 0.75] -1.16 12 .270 
Inhibition 9.15 3.31 10 -0.92 [-2.85, 1.16] -0.92 12 .375 
Switching 8.77 2.28 10 -1.95 [-2.61, 0.15] -0.24 12 .075 
List Sorting 93.58 14.4 100 -6.42 [-15.13, 2.28] -1.61 12 .134 
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Pattern Comparison 74.95 15.18 100 -25.05 [-34.22, -15.87] -5.95 12 .000* 
Flanker 88.62 21.03 100 -11.38 [-24.09, 1.33] -1.95 12 .075 
Card Sort 96.98 22.19 100 -3.02 [-16.43, 10.38] -0.49 12 .632 
 
Note: M, Mean; S.D. standard deviation; CI, Confidence Interval; df, degrees of freedom. 
Significance levels were determined by single sample t tests. Single asterisk (*) signifies 
a correlation is significant at the 0.05 level (2-tailed).  
 
 Correlations Between Measures of EF.  Correlations between D-KEFS’ scores 
was examined first. On the TMT, scores between TMT1, TMT2, TMT3 and TMT4 were 
all positive correlated (p values: .048 - .001). TMT5 was not significantly correlated 
within any other D-KEFS subtests examined (p > .05).  On Verbal Fluency subtests, VF2 
was positively correlated with VF1 and VF3 (p = .035 and p = .005); VF3 total correct 
and switching accuracy were correlated (p = .002).  None of the CWI subtests were 
correlated (p >.05).  Across measures on the DKEFS, VF1 was correlated with TMT4, 
CW1 and CW3 (p = .020, p = .044, p = .011, respectively). VF2 was positively correlated 
with TMT3, CW3 and CW4 (p = .018, p = .020, p = .048).  
 Correlations among subtests of the Toolbox were examined next. List Sorting, 
Flanker, and Card Sort Scores were all positively correlated (p values = .009 - .001). 
Pattern Comparison was not correlated with any Toolbox measure (p > .05).  
 Correlations between DKEFS scores and NIH scores were examined next. Scores 
from the DCS, a measure of shifting, were significantly correlated with DKEFS VF: 
Switching Accuracy and VF1 (p = .036 and p = .013, respectively). Scores from the LS, a 
measure of working memory, were significantly correlated with DKEFS VF subtests: 
category fluency, switching total correct, and category switching accuracy (p = .011, p = 
.035, p = .012), as well as, DKEFS CW: shifting (p = .003). Flanker, a measure of 
attention and impulse control, was significantly correlated with DKEFS VF switching 
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accuracy (p = .013). Scores from the PC, a measure of processing speed, were positively 
correlated with DKEFS TMT: Motor Coordination (p = .040).  
 Lastly, correlations between self-report measures of EF and neuropsychological 
measures of EF (NIH Toolbox, D-KEFS: TMT4, VF, CW3 and CW4) were examined 
next.  While BIS and DERS were elevated, they were not correlated with 
neuropsychological measures of EF (all p-values > .05).  Follow up analyses examining 
correlations between simpler measures of attention and processing speed and self-report 
measures of EF.  Please see for Table 4 for exact p-values and correlation coefficients.  
Table 4. Correlations Between Measures of Executive Function 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1 trails1 - .56* .70** .60* -.16 .49 .52 .25 .17 .52 .14 .56* .42 .30 -.22 .47 .41 0.03 0.52 0.34 
2 trails2 .048 - .81** .58* -.15 .19 .35 .39 .25 .19 -.13 .43 .13 -.04 -.13 .13 .23 -0.39 0.04 0.21 
3 trails3 .007 .001 - .75** .06 .48 .64* .50 .23 .38 .01 .54 .36 .34 -.26 .29 .44 -0.28 0.19 0.14 
4 trails4 .031 .038 .003 - .24 .63* .42 .17 .16 .44 .35 .52 .39 .28 -.20 .43 .51 -0.08 0.02 0.14 
5 trails5 .600 .636 .856 .426 - .34 .03 .32 .29 -.00 .54 .03 .15 .31 .58 .50 .37 -0.05 -0.24 -0.12 
6 vf1 .092 .545 .095 .020 .256 - .59* .18 .05 .57* .35 .68* .32 .41 -.13 .52 .59 -0.12 0.10 0.37 
7 vf2 .068 .240 .018 .158 .917 .035 - .73** .44 .45 -.02 .63* .56* .67 -.33 .33 .50 -0.12 0.07 0.22 
8 vf3 .416 .184 .079 .579 .284 .568 .005 - .77** .26 -.05 .43 .40 .59 .16 .39 .43 -0.23 -0.02 -0.09 
9 vf3 .581 .411 .445 .599 .343 .877 .132 .002 - .26 .07 .24 .43 .67 .23 .67 .67 -0.03 0.05 0.14 
10 cwi1 .067 .542 .204 .132 .996 .044 .125 .388 .399 - .36 .52 .32 .31 .15 .37 .31 -0.29 0.35 -0.08 
11 cwi2 .657 .682 .971 .239 .059 .239 .956 .875 .825 .227 - -.04 .40 .23 .36 .32 .22 -0.20 -0.31 -0.02 
12 cwi3 .047 .146 .055 .072 .929 .011 .020 .146 .434 .069 .890 - .44 .36 -.25 .46 .50 0.07 0.28 0.06 
13 cwi4 .152 .675 .229 .185 .631 .284 .048 .181 .146 .286 .180 .129 - .76 -.10 .51 .54 0.37 0.18 0.16 
14 LS .330 .896 .255 .359 .299 .165 .011 .035 .012 .301 .460 .224 .003 - -.14 .69** .81** 0.23 0.18 0.25 
15 PC .461 .672 .386 .514 .040 .670 .276 .598 .443 .620 .227 .420 .737 .641 - .48 .68 -0.14 0.06 -0.24 
16 FL .109 .672 .331 .140 .084 .068 .276 .185 .013 .221 .282 .117 .072 .009 .482 - .90** 0.26 0.38 0.40 
17 CS .162 .459 .130 .073 .213 .036 .084 .139 .013 .305 .464 .087 .057 .001 .679 .000 - 0.13 0.20 0.49 
18 DERS .913 .194 .360 .801 .884 .690 .696 .442 .914 .336 .507 .828 .213 .453 .642 .384 .679 - 0.48 0.11 
19 BIS-11 .071 .900 .538 .943 .436 .734 .827 .942 .885 .247 .308 .349 .554 .552 .858 .201 .520 .098 - 0.14 
20 WBSI .254 .497 .654 .641 .692 .209 .461 .775 .643 .801 .960 .849 .605 .410 .435 .176 .093 .733 .640 - 
 
Note: M, Mean; S.D. standard deviation; CI, Confidence Interval; df, degrees of freedom; 
vf1, Verbal Fluency: Letter Fluency; vf2, Verbal Fluency: Category Fluency; vf3; Verbal 
Fluency: Switching Fluency; vf3a, Verbal Fluency: Switching Fluency Accuracy; cwi1, 
Color Word Inhibition: Word Reading; cwi2, Color Word Inhibition: Word Reading; 
cwi3: Color Word Inhibition: Inhibition; cwi3, Color Word Inhibition: Switching; LS, 
List Sorting; PC, Pattern Completion; FL, Flanker; CS, Card Sort; BIS, Barrett 
Impulsivity Scale; WBSI, White Bear Suppression Inventory; DERS, Difficulties in 
Emotion Regulation Scale. The upper values represent Spearman’ rho and the lower 
corresponding p values. Significance levels were determined by Spearman’s Rank Order 
correlations. Single asterisk (*) signifies a correlation is significant at the 0.05 level (2-
tailed). Double asterisk (**) signifies a correlation is significant at the 0.01 level (2-
tailed). 
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 Exploratory Analysis: Correlations Between EF and Symptoms.  Self-report 
measures of worry (PSWQ), perceived stress (PSS), and depressed mood (BDI) were 
generally not correlated with neuropsychological measures of EF.  BDI was positively 
correlated with performance on color word inhibition switching (rs = .604, p = .049) and 
Pattern Comparison was negatively correlated with State Anxiety (rs = -0.636, p = .026). 
However, DERS total score was positively correlated with BDI (rs = 0.756, p = .007), 
PSWQ (rs = 0.715, p = .006), STAI-Trait (rs = 0.783, p = .003), and PSS (rs = .742, p = 
.004). WBSI was correlated with BDI (rrs = .689, p = .019). No significant correlations 
were observed between DERS total, WBSI, or BIS (all p values < .05) and or between 
BIS and measures of mood or anxiety.  
 Use of substance of abuse in the past 90 days was positively correlated with Trails 
4 (rs = 0.599, p = .031).  Use of any substance was negatively correlated with card sorting 
(rs = -.611, p = .027). No significant correlations between use and measures of mood or 
self-reported EF were found (all p-values > .05).  Please see Table 5 for correlations 
between EF and self-report measures of mood, anxiety, mindfulness and substance use.  
Table 5 
Correlations between Executive Function and Symptom Measures 
 
 
EF BDI-2 PSS PSWQ STAI-S STAI-T KMIS MAAS VAS ADCQ+ ADCQ- 
1 0.15 0.621 
-0.12 
0.692 
-0.29 
0.342 
-0.01 
0.964 
-0.19 
0.546 
0.06 
0.851 
0.1 
0.752 
-0.42 
0.176 
-0.39 
0.185 
0.23 
0.452 
2 -0.09 0.777 
-0.18 
0.565 
-0.34 
0.252 
0.05 
0.87 
-0.3 
0.344 
0.52 
0.07 
0.21 
0.485 
-0.28 
0.38 
-0.19 
0.54 
-0.04 
0.91 
3 -0.03 0.936 
-0.18 
0.556 
-0.4 
0.17 
-0.06 
0.862 
-0.19 
0.555 
0.21 
0.499 
0.26 
0.399 
-0.09 
0.785 
-0.32 
0.29 
-0.15 
0.619 
4 0.08 0.804 
0.01 
0.975 
-0.26 
0.397 
0.02 
0.943 
0.16 
0.622 
0.22 
0.478 
0.12 
0.704 
0.16 
0.621 
-0.23 
0.443 
0 
0.993 
5 -0.29 0.345 
-0.38 
0.207 
-0.02 
0.95 
-.61* 
0.034 
0.01 
0.981 
-0.05 
0.868 
-0.06 
0.845 
0.08 
0.814 
.64* 
0.019 
0.18 
0.553 
6 0.01 0.964 
-0.33 
0.265 
-0.24 
0.436 
-0.33 
0.303 
-0.04 
0.905 
-0.12 
0.709 
-0.37 
0.211 
0.27 
0.401 
-0.05 
0.863 
-0.03 
0.917 
 58 
7 0.1 0.747 
-0.15 
0.62 
-0.39 
0.186 
-0.11 
0.744 
-0.14 
0.675 
-0.15 
0.617 
0.02 
0.949 
0.18 
0.578 
-0.34 
0.257 
-0.31 
0.297 
8 -0.19 0.535 
-0.27 
0.374 
-0.37 
0.216 
-0.51 
0.091 
-0.28 
0.383 
0.09 
0.771 
0.17 
0.591 
-0.21 
0.522 
0.06 
0.838 
0 
0.993 
9 0.08 0.807 
0.01 
0.986 
-0.01 
0.975 
-0.36 
0.245 
0.14 
0.668 
-0.13 
0.669 
-0.16 
0.61 
-0.16 
0.618 
0.19 
0.53 
0.29 
0.345 
10 -0.16 0.594 
-0.27 
0.375 
-0.47 
0.107 
-0.42 
0.17 
-0.27 
0.401 
0.17 
0.589 
0.02 
0.961 
-0.27 
0.403 
-0.11 
0.72 
0.34 
0.257 
11 -0.17 0.591 
-0.5 
0.082 
-0.4 
0.181 
-0.2 
0.544 
-0.15 
0.635 
-0.02 
0.96 
0 
0.989 
0.08 
0.817 
.59* 
0.034 
0.36 
0.227 
12 0.15 0.624 
-0.09 
0.771 
-0.3 
0.327 
-0.3 
0.353 
0.02 
0.956 
0.27 
0.374 
-0.27 
0.381 
-0.1 
0.75 
-0.39 
0.193 
0.21 
0.499 
13 .60* 0.031 
0.12 
0.728 
-0.09 
0.783 
0.23 
0.479 
0.36 
0.257 
-0.25 
0.415 
-0.12 
0.707 
0.15 
0.652 
-0.15 
0.62 
0.07 
0.823 
14 0.42 0.159 
0.06 
0.847 
0.02 
0.947 
-0.06 
0.858 
0.36 
0.249 
-.59* 
0.035 
-0.31 
0.311 
0.25 
0.435 
-0.04 
0.889 
0.01 
0.964 
15 -0.4 0.171 
-0.36 
0.223 
0.04 
0.901 
-.64* 
0.026 
-0.29 
0.354 
0.24 
0.423 
0.12 
0.686 
-0.47 
0.127 
.67* 
0.012 
0.42 
0.158 
16 0.28 0.348 
-0.04 
0.907 
0.2 
0.523 
-0.41 
0.184 
0.34 
0.276 
-0.31 
0.307 
-0.49 
0.093 
-0.17 
0.594 
0.17 
0.587 
0.48 
0.094 
17 0.35 0.243 
0 
1 
0.12 
0.705 
-0.2 
0.529 
0.42 
0.171 
-0.42 
0.156 
-.56* 
0.049 
0.13 
0.68 
0.05 
0.864 
0.22 
0.467 
18 40 0.176 
0.33 
0.271 
0.39 
0.19 
-0.04 
0.901 
0.23 
0.47 
-0.19 
0.538 
-0.12 
0.689 
-0.46 
0.129 
-0.48 
0.1 
0.28 
0.36 
19 .78** 0.002 
.74** 
0.004 
.72** 
0.006 
0.41 
0.184 
.78** 
0.003 
-0.4 
0.184 
-0.23 
0.446 
0.15 
0.64 
-0.43 
0.146 
0.05 
0.865 
20 0.45 0.126 
0.01 
0.982 
0.37 
0.217 
0.34 
0.286 
0.23 
0.468 
-0.53 
0.063 
-.59* 
0.035 
0.23 
0.482 
0 
0.996 
-0.21 
0.497 
 
Note: EF, Executive Function Variable; BDI-2, Beck Depression Inventory; PSS, 
Perceived Stress Scale; PSWQ, Penn State Worry Questionnaire; State Trait Anxiety 
Inventory-State, STAI-S; STAI-T, State Trait Anxiety Inventory-Trait; KIMS-T, 
Kentucky Inventory of Mindfulness Skills- Total; MAAS, Mindful Attention Awareness 
Scale; VAS, Visual Analogue Scale; ADCQ, Alcohol and Drug Consequences 
Questionnaire; 1, Trails 1; 2, Trails 2; 3, Trails 3; 4, Trails 4; 5, Trails 5; 6, Verbal 
Fluency: Letter Fluency; 7, Verbal Fluency: Category Fluency; 8; Verbal Fluency: 
Switching Fluency; 9, Verbal Fluency: Switching Fluency Accuracy; 10, Color Word 
Inhibition: Word Reading; 11, Color Word Inhibition: Word Reading; 12, Color Word 
Inhibition: Inhibition; 13, Color Word Inhibition: Switching; 14, List Sorting; 15, Pattern 
Completion; 16, Flanker; 17, Card Sort; 18, Barrett Impulsivity Scale; 19, White Bear 
Suppression Inventory; 20, Difficulties in Emotion Regulation Scale. Significance levels 
were determined by Spearman’s Rank Order correlations. The upper values represent 
Spearman’ rho and the lower values represent the corresponding p values. Single asterisk 
(*) signifies a correlation is significant at the 0.05 level (2-tailed). Double asterisk (**) 
signifies a correlation is significant at the 0.01 level (2-tailed). 
 
Specific Aim 4: Examine Topological Properties of fNIRS Resting State Networks 
 Connectivity matrices were generated for HbO, HbR, and HbT maps for each 
participant and at the group level. A sparsity threshold (number of existing edges: 
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maximum number of edges possible) was applied to remove spurious correlations 
between channels. Each participants’ connectivity matrices were empirically thresholded 
over a range of 0.1<sparsity<0.5 (interval 0.01) to create sparse, positive binary networks 
Please see Figure 2 for an example.  
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Figure 2. Example connectivity matrices across sparsity thresholds. Example fNIRS 
resting-state functional connectivity matrix at the individual level (right) and group level 
(left) calculated using Pearson Correlation Coefficients (A) and corresponding matrices at 
varying sparsity thresholds (B). 
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 Topological properties of the network were then calculated across sparsity 
thresholds.  For the purposes of this study, the analyses were limited to eight metrics 
generated from the HbO maps: five measures reflecting small world properties; two 
measures of efficiency (network efficiency and local efficiency), and one measure at the 
nodal level (degree centrality).  Area Under Curve (AUC) values were examined for 
small world metrics and efficiency metrics from the HbO, HbR, and HbT maps.  
 Across sparsity thresholds, small world network parameters were generally 
supported.  Small Worldness is detected in networks where Gamma (γ) was greater than 
1, Lambda (λ) at or slightly greater than 1, and was Sigma (σ) greater than 1. Clustering 
coefficient (Cp) varied across thresholds (M 0.43= at 0.1 to Mean = 0.71 at .4). The ratio 
of the clustering coefficient of the network to the clustering coefficient of the random 
network (gamma), at a given threshold, however was greater than 1 across thresholds (M 
= 1.97 at 0.1; M = 1.17 at 0.4). The shortest path length (Lp) varied across sparsity 
thresholds (M = 4.51 at 0.1; M = 1.47 at 0.4). The ratio of the shortest path length of the 
network to the shortest path length in randomly generated networks (lambda), was 
slightly above 1 across thresholds (M = 1.27 at 0.1; M =1.03 at 0.4). Finally, sigma (ratio 
of gamma to lamba) in the network was greater than 1 across thresholds (M = 1.59 at .01; 
1.14 at 0.4), meaning the network has greater than random clustering and near random 
path length. Small world metrics across sparsity thresholds are displayed in Figure 3.   
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Figure 3.Small World Metrics. Results of clustering coefficient (A), shortest path length 
(B), Gamma (C), Lambda (D), and Sigma (E) areas as a function of sparsity threshold. 
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 Global efficiency (eg) varied across thresholds (M = 0.24 at .1; M = 0.63 at .4) as 
did local efficiency (Eloc) (M = 0.51 at .1; M = 0.81 at .4).  Degree centrality was 
calculated for each node using AUC scalar value. Mean degree Centrality across all 
channels was 9.48 (SD = 5.47).  Network Efficiency metrics across sparsity thresholds 
are displayed in Figure 4.   
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Figure 4. Network Efficiency Metrics. Results of global efficiency (A) and local 
efficiency (B) as a function of sparsity threshold.   
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Finally, the AUC for the five small world metrics and two efficiency  metrics were 
examined in the HbO, HbR and HbT maps separately. AUC values for each of the seven 
metrics calculated for each map are displayed in Figure 5. 
 
 
Figure 5. Area Under Curve (AUC) values for network measures: Sigma, clustering 
coefficient (Cp), Gamma, Lambda, shortest path length (Lp), global efficiency (Eg), and 
local efficiency (Eloc). Color bars represent: HbO, oxy-hemoglobin; HbR, deoxy-
hemoglobin; and HbT, Total-hemoglobin. 
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BIS total score was negatively correlated with aSigma and aGamma (r = -.708, p = .01 
and r = -.636, p = .026). Total score on the WBSI was negatively correlated with local 
efficiency (aEloc) (r = -.597, p = .040).   
 An exploratory follow up analysis examining correlations between BIS subscales 
and the seven graph metrics (Gamma, Sigma, Lambda, Cp, Lp, Eg and Eloc) was 
conducted. Of the second level factors (Attention, Motor, and Planning), the BIS Motor 
Scale was negatively correlated with aSigma and aGamma (r = -.752, p = .005; r = -.689, 
p = .013). Across subscales, the BIS perseverance subscale was negatively correlated 
with aSigma and aGamma (r = -.814, p = .001 and r = -.788, p = .002), and the BIS 
cognitive instability, a subscale of Planning, was positively correlated with shortest path 
length (aLp) r = .601 (p = .039).  See Table 6 for exact correlations and p-values.  
Table 6 
 
Correlates between EF and Graph Metrics 
 
Measure Sigma Cp Gamma Lambda Lp Eg Eloc 
Trails 1 -.60* -.12 -.73** .28 .31 -.30 -.41 
.039 .705 .008 .373 .328 .342 .181 
Trails 2 -.12 -.14 -.27 -.14 -.09 .22 -.08 
.709 .674 .399 .669 .785 .493 .810 
Trails 3 -.36 .17 -.32 .27 .03 .06 .02 
.257 .590 .309 .405 .922 .844 .948 
Trails 4 -.27 -.21 -.27 .15 -.11 .14 -.02 
.397 .516 .395 .643 .728 .662 .944 
Trails 5 .06 -.07 .37 .49 .05 .00 .24 
.857 .828 .240 .107 .890 .991 .455 
VF 1: Letter Fluency -.29 .12 -.35 .24 .33 -.43 -.20 
.366 .706 .260 .444 .291 .169 .540 
VF 2: Category 
Fluency 
-.22 .37 -.18 .19 .20 -.35 -.13 
.500 .236 .572 .563 .534 .267 .690 
VF 3: Switching 
Fluency  
-.10 .31 .13 .33 .18 -.17 .03 
.754 .331 .692 .293 .581 .592 .930 
 67 
VF 3: Switching 
Accuracy  
-.10 -.13 .07 .22 .00 -.00 -.07 
.759 .689 .827 .485 .991 .991 .826) 
CWI 1: Color Naming  -.15 .27 -.20 .22 .000 -.11 .10 
.639 .395 .540 .499 1.000 .740 .756 
CWI 2: Word Reading .33 -.22 .26 .18 -.36 .27 .34 
.302 .503 .410 .576 .252 .400 .276 
CWI 3: Inhibition  -.59* .27 -.50 .44 .50 -.50 -.30 
.04 .40 .10 .16 .10 .10 .35 
CWI 4: Switching -.082 -.105 .000 .218 -.156 -.036 -.013 
.800 .746 1.000 .495 .628 .911 .969 
List Sorting -.19 .10 .01 .40 .01 -.14 .01 
.548 .759 .966 .193 .974 .656 .965 
Pattern Comparison  .20 -.22 .32 .10 -.03 .03 .10 
.527 .500 .319 .770 .931 .940 .761 
Flanker -.48 -.34 -.36 .47 .31 -.32 -.34 
.111 .285 .255 .121 .331 .318 .279 
Card Sort -.32 -.15 -.23 .34 .12 -.14 -.16 
.309 .650 .467 .276 .711 .662 .622 
DERS -.47 -.38 -.32 .13 .30 -.38 -.50 
.124 .229 .319 .688 .354 .221 .099 
BIS-11 -.71* -.05 -.64* .30 .46 -.46 -.47 
.010 .870 .026 .353 .131 .134 .120 
WBSI -.05 -.51 -.46 -.48 .12 -.27 -.60* 
.866 .088 .129 .119 .720 .401 .040 
 
Note: VF, Verbal Fluency; CWI, Color Word Inhibition; BIS, Barrett Impulsivity Scale; 
WBSI, White Bear Suppression Inventory; DERS, Difficulties in Emotion Regulation 
Scale; Cp, clustering coefficient; Lp, shortest path length; Eg, global efficiency; Eloc, 
local efficiency. Significance levels were determined by Spearman’s Rank Order 
correlations. In each cell, the top value represent Spearman’ rho and the lower value 
represents the corresponding p value. Single asterisk (*) signifies a correlation is 
significant at the 0.05 level (2-tailed). Double asterisk (**) signifies a correlation is 
significant at the 0.01 level (2-tailed). 
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DISCUSSION 
 The primary aim of the study was to assess the feasibility of implementing a pilot 
RCT of MBRP within an outpatient substance use and methadone clinic from a 
neuropsychological framework.  The continued increase in opioid overdose death rates in 
the United States is of grave concern and the need for additional treatments to better 
serve individuals with OUD cannot be understated.  While recruitment efforts were 
targeted to adolescents and young adults, only young adult participants were successfully 
recruited.  The feasibility of using both neuropsychological measures of EF and fNIRS, 
in addition to measures of substance use and mood, in the context of a RCT was 
demonstrated.   The recruited sample demonstrated more variability in substance use 
history, more severe markers of psychopathology and greater unemployment rates than 
expected.  However, none of the baseline variables measured was associated with 
attendance of the follow up session, with the exception of number of prescribed 
psychiatric medications.  Overall, measures of executive function were within normal 
limits relative to the normative data, with the exception of one measure of processing 
speed. When EF performance variability was examined, however, a significant 
proportion of the sample had several scores in the impaired range, supporting the notion 
that EF is a multifactorial construct that may be best captured with multiple measures. 
This finding was supported by the limited number of significant correlations identified 
between the different measures of EF assessed in the study.  Finally, resting state 
functional connectivity networks were successfully measured using fNIRS. Preliminary 
findings provided support for identifying small world networks using fNIRS.      
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 The distinction between feasibility in a logistical sense and feasibility of the 
scientific methods employed in this study is worthy of consideration.  Significant 
logistical constraints impacted the implementation of the study, including limitations in 
staff involved in study procedures, shifting between locations, and challenges related to 
retention.  While these constraints impacted the overall sample size and power to detect 
changes, the scientific methods utilized were found to be feasible.  EF was measured 
using several reliable and valid instruments; multiple clinical symptom measures were 
administered; fNIRS was successfully used to collect resting state network data; and 
topological properties of resting-state networks were identified with fNIRS data.  Further, 
the treatment intervention was successfully implemented and randomization did not 
appear to impact follow-up rates.   
Feasibility Issues: Recruitment and Retention  
 20 participants were consented, 13 participants were randomized to condition, and 
six participants completed through to the follow-up visit.  While no specific baseline 
characteristics were found to be predictive of attendance of follow-up visit, with the 
exception of psychiatric medication use, continued care at the facility throughout the 
study was likely a contributing factor.  While patients receiving care at a methadone 
clinic are in many ways a “treatment seeking” population, the level of motivation and 
interest for additional behavioral treatments within this population is unknown.  
Motivation and readiness to make behavioral changes, on any level, fluctuates throughout 
the course of a given day or stage in behavior change. This is natural and expected. While 
a significant number of individuals present to the clinic daily for ORT, appearing to the 
clinic for ORT may not be not be synonymous with seeking additional intervention.  
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 Adolescents remain a population that underutilizes treatments for OUD.  There is 
a significant need for treatments that target younger individuals.   In this study, 
individuals under the age of 18 were not recruited despite significant efforts to target this 
subset of the treatment population, specifically. In part, the reduced flow of adolescent 
patients in the clinic and the increased severity of symptoms among those that were 
receiving care at the time of the study are likely contributing factors. However, there 
were some adolescents and families that did receive care at the clinic and were not 
interested in additional options.  It is possible that at the time of study contact, a relapse-
prevention framework was not an appropriate clinical fit.  Clients experiencing 
withdrawal, currently being stabilized on an ORT, or still experiencing significant 
ambivalence about making changes in opioid use behaviors would not be a good fit for a 
relapse prevention program. Nonetheless, it would be helpful to better understand what 
factors impact treatment engagement among adolescents.  One way to address this would 
be via qualitative methodology.  
 A qualitative approach may help to better identify barriers to treatment perceived 
by adolescents and their family members.  Clearly, developing treatments that target 
adolescents are needed and understanding what factors impact engagement is a good first 
step.  The majority of participants recruited in this study began using substances in their 
teens, yet on average there was nearly an 8-year lag between first use and first treatment 
encounter.  A better understanding from their perspective would also help identify factors 
that may have motivated eventual engagement in services.   Increased effort to gain 
support from family members would likely increase treatment engagement among 
adolescents, as well. Perhaps this could be accomplished via a brief presentation to 
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parents and family members at possible clinic orientation sessions.  Since the vast 
majority of the recruited sample reported their first encounter with mental health 
providers occurred during adolescence, perhaps targeting substance use interventions to 
adolescents receiving mental health treatment might be a useful approach.    
 Approximately, half of the sample attended the final follow up session. With the 
exception of number of psychiatric medications prescribed, none of the baseline variables 
measured were found to be significantly associated with attendance at the follow up 
session. Given the small sample size, power to detect small to medium effect sizes was 
limited.  Consistent care within the treatment facility, however, did appear to be an 
important factor for follow-up attendance.   
Clinical Characteristics of the Recruited Sample 
 The recruited sample demonstrated variability in substance use history, severe 
markers of psychopathology, and significant unemployment rates. Most of the sample 
reported use of two or more substances when using their drug of choice, and over three 
quarters of the sample reported a history of concurrent abuse of opioid and stimulants. 
Substance use disorders are diagnosed by drug of abuse and consequently, treatment 
outcomes both clinically and in research contexts focus on the identified drug of abuse. 
This approach does not fully capture substance use patterns among all individuals with 
SUD. In particular, it fails to capture polydrug use, comorbid SUDs, and development of 
later SUDs during the course of care.    
 Approximately, one third of the sample reported using the substance of abuse in 
the past 90 days, however, nearly three-quarters of the sample reported use of a different 
substance of abuse. This finding highlights the complexity of assessing treatment 
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outcomes in this population. Methods for how to handle and detect the occurrence of new 
“addictions” during the course of treatment are needed.  Abuse of prescription 
medications, alcohol or marijuana may emerge during the course of ORT treatment.  A 
significant portion of the sample reported use of cannabis, as well as nicotine.   Instances 
of using prescribed medications in ways that were not prescribed, was also reported.   
Identifying the best treatment targets can be a dynamic process.  Over the course 
of treatment, it may be necessary to reassess substance use patterns periodically. While a 
harm reduction approach makes sense at initiation of treatment, as clients become 
stabilized on an ORT, new substances of abuse may become increasingly problematic.  
As mentioned, many of the participants reported use of cannabis. Notably, there have 
been efforts to use cannabis as a treatment for OUD and it has been added to the list of 
conditions for which medical marijuana may be prescribed in New Mexico (Kunkel, 
2019).  While from a harm reduction perspective this may prevent overdose deaths, it 
also has the potential to foster additional substance use disorders.  The latest research also 
suggests cannabis may not be associated with reduced overdose deaths in the long run 
(Shover, Davis, Gordon, & Humphreys, 2019) and may be associated with increased 
psychosis (Shover, Shoptaw, et al., 2019). Perhaps, effort to develop new behavioral 
treatments for OUD might be a better use of resources.    
 The prevalence of comorbid psychopathology was well documented in this 
sample. All participants reported being diagnosed with at least one additional psychiatric 
disorder and a significant proportion were on multiple psychotropic medications in 
addition to ORT or naltrexone.  While there was a significant lag between initiation of 
substance use and first encounter with substance use treatment, participants had a history 
 73 
of early mental health treatment.  In fact, the average age for first drug use and first 
mental health encounter were within the same 12-month period.  Continued difficulty 
with mental health symptoms was reported at the time of the study as well, with 
participants reporting symptoms of anxiety and low mood.  This finding highlights the 
need for interventions that can address the complex comorbid mental health issues that 
often arise among individuals with OUD.  Further, the self-report measures of EF 
included measures of emotion regulation and coping strategies. Participants reported 
reduced coping strategies and impaired ability to regulate emotions, providing additional 
support for the future use of MBRP in this population. As previously mentioned, MBRP, 
in particular, has been shown to be helpful with aspects of emotion regulation.  
Executive Functioning at Start of Study 
 When compared to the normative sample, at a group level, participants in the 
study scored within between the 21st and 60th percentile on measures of executive 
function, with the exception of one measure of processing speed, which was at the 5th 
percentile. However, when the number of impaired EF scores was examined per 
participant, a significant proportion of the sample had one or more scores in the impaired 
range (below the 5th percentile).  This finding supports the idea of EF as a multifactorial 
construct that is not easily measured by a single test or score.  Non-significant 
correlations between measures of EF within this sample provide tentative further support 
for using multiple measures of EF to capture EF impairments. In future work, it would be 
helpful to generate a single measure of EF in addition to measures of specific EFs.  In 
larger samples this could be done using a principal components analysis or by averaging 
standardized scores.  The EF tests selected for this study captured a range of EFs, 
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however, in future work it may be useful to limit analyses to scores that capture the most 
demanding aspect of the task (e.g., Trails 4, but not Trails 1, 2, 3 and 5; color word 
inhibition and color word inhibition switching, but not color naming and word reading).  
 Interestingly, while self-reported EF problems were not correlated with 
performance on objective measures of EF, there were some correlations between self-
report measures of EF and measures of mood and anxiety.  The relationship between self-
reported EF problems and other symptom measures has been examined in other 
populations, such as mild Traumatic Brain Injury (Rapoport, McCullagh, Shammi, & 
Feinstein, 2005; Schiehser et al., 2011). It may be useful to consider self-reported EF in 
the context of other mental health conditions in future research.  In particular, in the 
treatment studies, it would be interesting to assess if treatment response to self-report 
measures of EF differs from treatment response to objective measures of EF. 
 Additional measures of EF, not used in the current study should be explored in 
future work. Specific to cool EFs, measures of planning, such as the Tower of London 
and measures of sustained attention would be informative.  The variability in 
performance across measures of EF could, in part, be explained by a weakness in 
sustained attention.  It is also possible that the variability in performance across tests 
could be explained by effort.  In future studies, an objective measure of effort would be 
very informative.  
 Finally, hot EF tasks seem particularly relevant for this population.  There were 
challenges associated with administering a hot EF task in this study.  Hot EF tasks, 
including the one used in this study, can be time consuming. This can pose a real 
challenge for researchers administering a larger battery of cool EF tasks.  In this study, 
 75 
the hot EF task was administered last in the sequence of measures to prevent the hot EF 
task from influencing performance on the cool EF tasks.  This could theoretically impact 
skew performance on the hot EF task if individuals are more fatigued when the hot EF 
task is administered.  Among clinical samples it is important to consider when the task 
might be too distressing for a given participant, as well.  It would be helpful to develop a 
standardized procedure for determining if a task is too distressing for participants.  
Similarly, a set of standardized procedures for follow-up support for participants after the 
task would be worth further consideration. Additional hot EF tasks should be explored in 
this population as well.  Tasks that capture decision-making and delayed discounting, for 
instance, would be particularly relevant for SUD treatment samples.  Likewise, 
administering EF tasks with embedded drug-cues would further our understanding of EF 
in the context of triggers to use substances. While hot EF tasks are relatively new in the 
field of EF research, these tasks have the potential to capture the real-world impairments 
of EF that may not always be captured by cool EF measures.  
 In future research it would be helpful to tie specific EF impairments to functional 
outcomes. For instance, perhaps an individual with impaired fluency might exhibit 
greater difficulty generating new solutions to a problem.  Alternatively, perhaps an 
individual with difficulty shifting on tasks of EF might demonstrate difficulties 
transitioning between home and work. It is important that one can connect impairments in 
EF in daily life with the EF impairments observed on study measures.    
fNIRS is Both Feasible and Useful 
 Findings supported the presence of small world properties in the fNIRS resting 
state networks in this study.  Exploratory analyses examining correlations between 
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network results and measures of EF, as well as, measures of mood, anxiety, substance 
use, and mindfulness were successfully performed.  This provides support that fNIRS can 
be utilized in clinical research in very meaningful ways.  fMRI research is very costly, 
yet provides important metrics for furthering our understanding of mental health 
problems. Resting state analyses, in particular have shown potential for meaningful 
clinical applications.   While fMRI research is still needed to examine subcortical resting 
state networks, fNIRS proves to be an effective and relatively inexpensive alternative.  
As was demonstrated in this study, fNIRS can be used successfully to generate these 
more complex network analyses and can easily be used to examine clinical correlates.   
 The current montage was selected to capture resting-state activity across the entire 
cortex.  While minor modifications could be explored (e.g., including additional channels 
in the prefrontal cortex and motor cortex) the general approach to montage creation was 
supported.  Further, while not explicitly examined in these analyses, fNIRS can be used 
to examine specific neuroanatomical regions, as well.  For instance, one could select 
specifically the nodes localized in the frontal regions for a ROI analysis. FC-NIRS 
toolbox can detect directed graphs and weighted graphs, as well. These analyses would 
be particularly relevant for measuring networks during tasks. Lastly, alternative analytic 
approaches could be applied to the fNIRS network as well, such as Independent 
Components Analysis.  
 Finally, while the power was limited, some findings were interesting and worthy 
of consideration in future research. First, small world network metrics were successfully 
detected using fNIRS. These parameters have been used to identify potential biomarkers 
of a variety of psychiatric conditions, including SUD.  Changes in small world metrics 
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would be an excellent target for treatment that can be captured by fNIRS and could be 
emphasized in an RO1 application.  Additionally, some preliminary correlations between 
the graph metrics and self-reported EF were observed.  Specifically, scores on a measure 
of impulsivity (BIS-2) was correlated with Gamma and Sigma, two metrics associated 
with small worldness. As mentioned earlier, a previous study of MBRP in OUD, found 
improvements on the BIS-2 in the MBRP group, but not the control group (Yaghubi, 
Zargar, & Akbari, 2017).  Perhaps, one potential mechanism for a reduction in 
impulsivity following MBRP is via increased small worldness in the resting state 
network.   
Limitations 
 The small sample size recruited and the drop-out rate were significant study 
limitations.  The impact of the MBRP on substance use, executive functioning, and 
resting state connectivity could not be determined. Regarding measures, self-report 
measures of substance use are less reliable than objective measure of substance use, such 
as might be found from a urine analysis.  Additionally, the study did not gather 
qualitative information from study participants, which could have guided future work. 
Finally, the participants recruited were heterogeneous in terms of comorbid psychiatric 
diagnoses, substance use history, and psychiatric medications. While homogenous, i.e., 
“clean”, samples are the gold standard during initial RCTs, often the clinical reality is one 
of greater complexity and heterogeneity. 
Conclusions 
 Pilot studies can help inform larger studies. Understanding the steps needed to 
implement an empirically supported treatment into different outpatient clinics is a 
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necessary step in the dissemination of research. The protocol was already modified for a 
treatment setting, which increased the feasibility greatly (Roos, 2019). More specifically, 
sessions were briefer, offered multiple times a week, and a rolling group format was 
utilized.  Frequently, providers express frustration or reluctance to adopt manualized 
protocols because there is a belief that clinical trials are not conducted in the “real 
world”.  Fortunately, robust treatments, such as MBRP, can withstand more complex 
populations.  Additional staff would be needed to successfully run this study at a larger 
scale.  More specifically, it would be beneficial to have a least one part time staff member 
(i.e. study coordinator) on site at the clinic to facilitate continued contact with clinic staff 
and interested participants.  Additionally, it would be helpful to have a second staff 
member present for active recruitment periods (i.e., during peak traffic times at the 
clinic). For baseline visits, two to three additional research assistants would enable 
participants to complete baseline measures more efficiently and would allow for multiple 
participants to be scheduled at once. Regarding therapy groups, ideally bi-weekly groups 
would be available at multiple time slots (i.e., four time slots) to capture both the morning 
wave and afternoon wave of participants. This would likely require three to four 
therapists.  Lastly, for an RO1 application, a case manager or social worker on staff to 
help with patient care coordination would be helpful and a psychiatrist or psychiatric 
nurse (0.25 FTE) would be helpful to have on site in the event of any medical crises (e.g., 
overdose).   
 Prevention and early intervention efforts are paramount.  The majority of 
individuals within this study began using substances in their teens, yet on average there 
was nearly an 8-year lag between first use and first treatment encounter.  Clearly, 
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developing treatments that target adolescents are needed.  The vast majority of the sample 
first experienced mental health issues in their teens as well.  Specific targeted prevention 
efforts should be implemented within pediatric mental health clinics. Additionally, more 
in depth assessment of substance use should be included in every mental health intake 
conducted in pediatric health settings.  Efforts to educate teachers and parents on 
substance use prevention should begin during elementary school given the early age of 
first substance use initiation.  Finally, preventive interventions that boost EF, such as a 
modified MBRP, could be implanted in school systems and are worth future 
consideration.  
 A neuropsychologically-informed approach is feasible.  At its core, 
neuropsychology is the study of brain-and-behavior relationships. The NIMH created the 
RDoC framework to further a dimensional approach to mental health, linking specific 
behavioral dysfunctions to specific neural circuits, reflecting a neuropsychological 
approach to mental health. Clinical Neuropsychology, as discipline, serves multiple roles 
including: development of treatment plans, formulation of accommodations needed to 
help an individual function, and in some contexts, prediction of treatment outcomes 
(Schoenberg, 2011).  While perceived cognitive deficits motivate referrals to 
neuropsychology, psychological symptoms are a consistent part of the clinical 
presentation.  Neuropsychology can make significant contributions in furthering our 
understanding of complex mental health conditions like SUD.   
 Advances in neuroimaging, in conjunction with a long history of clinical 
assessment, enables neuropsychology as a field to identify novel treatment targets for 
OUD.  Further, neuropsychology is well suited to assess treatment-induced changes on 
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validated, specific treatment targets over time through the use of neuropsychological 
assessments and neuroimaging methods.  An integration of neuropsychology with more 
traditional clinical trials research for mental health conditions like SUD is a worthy 
endeavor.  While neuropsychological methods are often time consuming, the findings in 
this study demonstrate this approach is not only feasible, but has the potential to link 
behavioral symptoms with neural circuits via fNIRS.   
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